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ABSTRACT  
Pancreatic islet transplantation represents a fascinating procedure that, at the 
moment, can be considered as alternative to standard insulin treatment or pancreas 
transplantation only for selected categories of patients with type 1 diabetes mellitus. 
Among the factors responsible for leading to poor islet engraftment, hypoxia plays an 
important role.  
Mesenchymal stem cells (MSCs) were recently used in animal models of islet 
transplantation not only to reduce allograft rejection, but also to promote 
revascularization. Currently adipose tissue represents a novel and good source of MSCs. 
Moreover, the capability of adipose-derived stem cells (ASCs) to improve islet graft 
revascularization was recently reported after hybrid transplantation in mice.  
Within this context, we have previously shown that hyaluronan esters of butyric and 
retinoic acids can significantly enhance the rescuing potential of human MSCs. Here we 
evaluated whether ex vivo preconditioning of human ASCs (hASCs) with a mixture of 
hyaluronic (HA), butyric (BU), and retinoic (RA) acids may result in optimization of 
graft revascularization after islet/stem cell intrahepatic cotransplantation in syngeneic 
diabetic rats. We demonstrated that hASCs exposed to the mixture of molecules are able 
to increase the secretion of vascular endothelial growth factor (VEGF), as well as the 
transcription of angiogenic genes, including VEGF, KDR (kinase insert domain 
receptor), and hepatocyte growth factor (HGF). Rats transplanted with islets cocultured 
with preconditioned hASCs exhibited a better glycemic control than rats transplanted 
with an equal volume of islets and control hASCs. Cotransplantation with 
preconditioned hASCs was also associated with enhanced islet revascularization in vivo, 
as highlighted by graft morphological analysis. The observed increase in islet graft 
revascularization and function suggests that our method of stem cell preconditioning 
may represent a novel strategy to remarkably improve the efficacy of islets-hMSCs 
cotransplantation.
1 - Introduction 
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1 - INTRODUCTION  
1.1 Diabetes 
Diabetes mellitus (DM) is a systemic metabolic disorder characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The 
chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, 
and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood 
vessels (Diabetes Care, 2008). 
This pathology, long considered a disease of minor significance to world health, is 
now taking its place as one of the main threats to human health in the 21
st
 century. 
Indeed, diabetes incidence appears to be rapidly rising in many parts of the world (fig. 
1.1): in the year 2000, 150 million people worldwide were diagnosed with DM, and this 
number is considered to double in 2025 (Zimmet et al., 2001).  
 
 
 
 
 
 
 
 
 
 
    
Pronounced changes in the human environment, behaviour and lifestyle have 
accompanied globalization, and these have resulted in escalating rates of both obesity 
and diabetes. In general, as countries become richer, people eat a more sugar- and fat-
Figure 1.1 - Numbers of people with diabetes (in millions) for 2000 and 2010 (top and 
middle values, respectively), and the percentage increase (Zimmet et al., 2001). 
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rich diet and are less physical active. On average, nearly 8% of adults living in high-
income countries have diabetes. It is, however, upper-middle and middle-income 
countries that have the highest prevalence of diabetes (fig. 1.2); over 10% of adults in 
these countries have the condition. The mortality rate of diabetes varies sharply with the 
prosperity of the country. In 2011, the disease caused more than 3.5 million deaths in 
middle-income countries, of which more than 1 million were in China and just less than 
a million were in India. Approximately 1.2 adults died of a diabetes-associated illness 
per 1,000 cases in 2011 in low- and middle-income countries: more than double the 
mortality rate of high-income countries, where the healthcare recourses are greater 
(Scully, 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several pathogenic processes are involved in the development of DM. These range 
from autoimmune destruction of the β-cells of the pancreas with consequent insulin 
deficiency to abnormalities that result in resistance to insulin action. The basis of the 
abnormalities in carbohydrate, fat, and protein metabolism in diabetes is the deficient 
action of insulin on target tissues. Deficient insulin action results from inadequate 
insulin secretion and/or diminished tissue responses to insulin at one or more points in 
the complex pathways of hormone action.  
Figure 1.2 - Tsunami of diabetes (Scully, 2012). 
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Long-term complications of diabetes include retinopathy with potential loss of 
vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot 
ulcers, amputations, and Charcot joints; and autonomic neuropathy causing 
gastrointestinal, genitourinary, and cardiovascular symptoms and sexual dysfunction. 
Patients with diabetes have an increased incidence of atherosclerotic cardiovascular, 
peripheral arterial, and cerebrovascular disease. 
The diagnosis of diabetes is based on measurement of fasting plasma glucose level, 
but also on measurement of plasma glucose concentration after an oral glucose load 
(glucose tolerance test). 
There are three main forms of diabetes: 
1. Type 1 diabetes (T1DM) is due primarily to autoimmune-mediated 
destruction of pancreatic β-cell islets, resulting in absolute insulin deficiency. 
It was previously referred to as "insulin-dependent diabetes mellitus" or 
"juvenile diabetes". Indeed, it is predominantly a disease of the young, 
usually developing before 20 years of age. T1DM makes up approximately 
10% of all cases of diabetes. Although it is numerically less prevalent than 
type 2 DM in the general population, it is one of the most common chronic 
diseases of children, developing in approximately 1 in 600 children. The 
incidence is relatively low for children under the age of 5, increases between 
5 and 15, and then tapers off. The most severe forms of DM are generally 
linked to this variant.  
2. Type 2 diabetes (T2DM), which accounts for almost 90% of all cases of 
diabetes in adults worldwide, is characterized by insulin resistance, a 
condition in which cells fail to use insulin properly, sometimes combined 
with abnormal insulin secretion. This form was previously referred to as “non 
insulin-dependent diabetes mellitus” or "adult-onset diabetes". A degree of 
hyperglycemia sufficient to cause pathologic and functional changes in 
various target tissues, but without clinical symptoms, may be present for a 
long period of time before diabetes is detected.  
3. The third main form, gestational diabetes, occurs when pregnant women 
without a previous diagnosis of diabetes develop a high blood glucose level. 
It may precede development of T2DM. 
1 - Introduction 
 
12 
 
In some individuals with diabetes, adequate glycemic control can be achieved with 
weight reduction, exercise, and/or oral glucose lowering agents. These individuals 
therefore do not require insulin. Other individuals who have some residual insulin 
secretion are not dependent on exogenous insulin, but may require it for adequate 
glycemic control if this is not achieved with diet alone or with oral hypoglycemic 
agents. Individuals with extensive β-cell destruction require insulin for survival to 
prevent the development of ketoacidosis. The severity of the metabolic abnormality can 
progress, regress, or stay the same. Thus, the degree of hyperglycemia reflects the 
severity of the underlying metabolic process and its treatment more than the nature of 
the process itself. 
1.2 Type 1 diabetes mellitus 
As already stated, T1DM is characterized by the autoimmune selective destruction of 
the insulin-producing β-cells of the pancreas, termed islets of Langerhans (Eisenbarth, 
1986). The absolute deficiency of insulin results in a wide spectrum of metabolic 
dysfunction, particularly impaired glucose homeostasis. T1DM pathogenesis involves 
environmental triggers that may activate autoimmune mechanisms in genetically 
susceptible individuals (table 1.1).  
 
 
 
 
The discovery of insulin in 1922 was a monumental achievement, transforming type 
1 diabetes mellitus from a death sentence to a manageable, chronic condition. The 
Diabetes Control and Complications Trial (DCCT) confirmed that tight glucose control 
prevents or even reverses long-term complications of type 1 diabetes (New Engl J Med, 
Table 1.1 - Possible aetiological factors in type 1 DM (Zimmet et al., 2001). 
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1993). However, insulin therapy itself can be life-threatening, as an overdose can result 
in severe hypoglycemia. In fact, tight glucose control is associated with more frequent 
episodes of hypoglycemia, especially in patients during acute illnesses (Krinsley et al., 
2011). Many patients experience wide excursions in plasma glucose levels that lead to 
the secondary complications of diabetes, since most existing insulin formulations cannot 
mimic the natural regulatory ability of the insulin-producing β-cells of the endocrine 
pancreas. Worthy to note, more recent innovations in insulin delivery and therapy, such 
as insulin degludec (an ultra-long-acting basal insulin analog that can last up to 40 
hours) has been shown to potentially mimic normal body glycemic control better than 
existing 24 hour-based regimens using long-acting insulin analog glargine.  
Many insulin-dependent type 1 diabetes patients have some degree of hypoglycemia 
unawareness, the inability to sense low blood glucose, thus the benefits of stringent 
glycemic control may be outweighed by the risk of a potentially fatal insulin overdose 
(Cryer, 2005). Up to 10% of mortality in patients with T1DM is the result of 
hypoglycemia unawareness (Cryer, 2008), which potentially causes loss of 
consciousness or inability to awaken from sleep (“dead-in-bed” syndrome) (Ragnar, 
1997). Despite advances in insulin therapy, the frequency of hypoglycemia unawareness 
has not declined in the past two decades (McCrimmon et al., 2010), thus alternative 
therapies are required (Jamiolkowski et al., 2012). 
1.3 Whole pancreas transplantation  
The first successful pancreas transplantations were simultaneous pancreas-kidney 
(SPK) transplants performed in 1966 in two patients with end-stage diabetic 
nephropathy (Kelly et al., 1967). One of the two recipients achieved near-normal 
glycemia for approximately two months. T1DM patients that have undergone a 
successful kidney transplant are candidates for pancreas-after-kidney (PAK) 
transplantation. SPK and PAK transplants have continued to improve quality of life and 
reduce hyperglycemia-related complications, while peri- and post-operative morbidity 
and mortality have steadily declined (Nathan, 2003).  
However, whole pancreas transplantation is intrinsically a major surgical procedure 
with a high procedure-related morbidity leading to reoperation rates of >40% and 
mortality rates of up to 4% (Johnson et al., 2012). Major complications include chronic 
immunosuppression, surgical complications, and graft rejection (Venstrom et al., 2003), 
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and are related to the transplanted pancreatic exocrine tissue rather than the endocrine 
component. As islets of Langerhans only comprise 2% of the pancreas, it could be 
argued that 98% of a whole pancreas transplant is surplus to requirement. Standard 
medical therapy with insulin and close glucose monitoring are safe and successful in 
most patients with type 1 diabetes, thus the American Diabetes Association believes that 
pancreas transplant alone (PTA) carries unjustified risks (JAMA, 1996; Robertson et al., 
2004).  
1.4 Pancreatic islet transplantation  
The aim of islet transplantation is to “reverse” diabetes by transplanting only the 
endocrine component of the pancreas (about 2% of the pancreas mass). The advantage 
of this procedure, that has always aroused attention from researchers, is avoidance of 
the major surgery needed for whole pancreas transplantation. As a cellular transplant it 
is minimally invasive, and it is associated with low morbidity and almost no mortality. 
However islets, though only clusters of 100-1,000 hormone-secreting cells with a 
diameter of 0.3-0.7 mm, obey the same immunological laws that govern solid organ 
transplantation, i.e. allogeneic islets trigger immune-mediated rejection that must be 
controlled with immunosuppressive drugs (Cardani et al., 2007). Noteworthy, isolated 
islets are potentially amenable to various types of manipulation/preconditioning that 
will enable these transplants to be performed in the future using minimal or even no 
immunosuppression. Islet transplantation therefore fulfills the criteria for an ideal 
treatment for reversing T1DM. The relative advantages and disadvantages of islet and 
whole pancreas transplantation are compared in table 1.2. It should be emphasized, 
however, that these two therapies are complementary rather than in competition, and 
that each form of β-cell replacement has merits for different patients (Johnson et al., 
2012). 
The modern era of islet transplantation began in 1972 with reports from two 
laboratories demonstrating successful reversal of diabetes in rodents by isolated islet 
transplantation (Ballinger et al., 1972; Reckard et al., 1973). Since then, a number of 
critical milestones have been achieved, including: 1) selection of the portal vein and 
liver as a site for inoculation of isolated islets (Kemp et al., 1973); 2) an automated 
method for isolation of human pancreatic islets (Ricordi et al., 1988); and 3) 
improvements in collagenase enzyme blend for isolation and purification of islets.  
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According to the Collaborative Islet Transplant Registry (CITR) report, the peri-
procedural complications of islet transplantation have an estimated 20-fold lower 
morbidity risk than pancreatic transplants (Sà et al., 2008). Another advantage of islet 
transplantation is that healthy islets can be isolated from pancreases that may not be 
used for whole organ transplantation, which is extremely valuable given the shortage of 
donors (Rother et al., 2004). 
 
 
 
 
1.4.1 Historical outlines 
The history of pancreatic islet transplantation is long. The first transplant of 
fragments of the pancreatic gland in order to cure diabetes dates back even to the 20
th 
December 1893, 28 years before the discovery of the insulin. Two English medical 
doctors from the Bristol Royal Infirmary Hospital, Dr. Watson-Williams and Dr. 
Table 1.2 - Comparison of islet and whole pancreas 
transplantation (Johnson et al., 2012). 
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Harsant, harvested a pancreas from a deceased sheep and transplanted three pieces of 
the gland into the subcuticular tissue of a 15-year-old boy with uncontrollable diabetic 
ketoacidosis. Obviously, despite a temporary improvement of the clinical situation, the 
xenotransplant failed after three days for acute rejection. 
After that first experiment almost one century passed before Paul Lacy and 
colleagues in 1967 developed the technique of islet isolation in rats. Two important 
innovations made this procedure possible: the injection of digestion enzyme solution in 
the pancreatic duct and the centrifugation with different density gradients to separate the 
islets from the discarding tissue. 
After few years the improvement of the glycemic control by intraperitoneal 
transplantation of islets was demonstrated in diabetic rats (Younoszai et al., 1970), and 
subsequently the liver, using the same experimental model, was selected as preferable 
implantation site (Kemp et al., 1973).  
The first clinical series of islet transplantation was reported in the late seventy using 
azathioprine and steroids as immunosuppressive therapy (Najarian et al., 1977). 
Although these first cases did not experience any complications, the efficacy of the 
transplant was very limited. Seven patients over seven failed to reach insulin 
independence after intraperitoneal or intraportal islet transplantation even though some 
of them reduced the need of exogenous insulin for a period.  
Interestingly the first real clinical success in the field of islet transplantation was 
reported in one case of combined islet-kidney transplantation performed on a T1DM 
uremic patient in Zurich in 1978. This patient reached insulin independence and 
maintained it almost one year after the embolization in the spleen of fragments of donor 
pancreas (Largiader et al., 1979).  
1.4.2 The Edmonton protocol  
Until the year 2000, islet transplantation was a highly successful procedure in animal 
models, with almost universal reversal of diabetes. However, translating these 
experimental results into human clinical trials was rather unsatisfying, especially for 
what concerned the long-term efficacy of the graft. In the 1990s, almost 500 islet 
transplants were performed in adults with severe T1DM, but the overall insulin-
independence rates achieved were only 11%, and the 3-year incidence of sustained graft 
function was 19% in selected patients (Brendel et al., 2001). 
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Surprisingly, in 2000 the team from the University of Edmonton (Canada) reported 
100% of insulin independence in seven consecutive T1DM patients at 1 year from islet 
transplantation (Shapiro et al., 2000). This landmark paper led to a resurgence of islet 
transplantation activity across the world, with centers using the “Edmonton Protocol” 
with 1-year insulin independence rates of 80-85% being achieved in leading centers. 
The “Edmonton Protocol” involved numerous small changes to existing protocols, but 
the principal factors that seem to have been responsible for the dramatically improved 
clinical outcomes include: firstly a second “top up” transplant being given to all patients 
within 3-6 months from the initial transplant, thereby ensuring that the recipient 
received a total of at least 11,000 islet equivalents (IEQ) per kg; secondly the use of a 
maintenance immunosuppressive regimen without steroids. 
Later, with the aim to assess the applicability and reproducibility of the results 
obtained from Edmonton group, a multicentric study started using the Edmonton 
protocol involving 9 transplant centers, 6 of which were American and 3 European. 
Data from this study reported in 2006 did not confirm however the Edmonton results, 
showing a high variability in transplantation outcome according to the isolation center 
(Shapiro et al., 2006).  
The critical passage in the procedure of islet transplantation is exactly the phase of 
organ processing in order to isolate the islets of Langerhans. These considerations lead 
to the development of several networks in which the isolation procedure is performed 
by few specialized and experienced centers and the islet transplantations are spread to 
several different centers even at long distance (Kempf et al., 2005).  
In 2008 the Collaborative Islet Transplant Registry reported approximately a 30% of 
insulin independence by 3 years post-operatively over 325 adult recipients which were 
treated between 1999 and 2007 with an islet alone or a combined kidney-islet 
transplantation. However, more than 75% of the recipients maintained a residual graft 
functionality detected by the endogenous secretion of C-peptide at 3 years from the 
transplantation.  
This apparently disappointing outcome showed anyway an important improvement in 
the quality of life of the patients reducing the episodes of severe hypoglycemia and the 
development of complications related to the diabetic disease (Alejandro et al., 2008). 
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1.4.3 Methodology of islet transplantation  
Islet transplantation involves four principal components (fig. 1.3), namely pancreas 
donation and retrieval, islet isolation, islet culture, and the islet transplant itself 
(including patient selection and the pre- and post-transplant patient management). 
Although a number of aspects of this treatment are readily available in many hospitals, 
islet isolation has remained a challenging procedure requiring considerable expertise, 
and, therefore, this has been centralized to a small number of highly specialized centers. 
Islets are then either transplanted at those centers or transported to “satellite” centers for 
infusion into patients (Johnson et al., 2012). 
 
 
 
1.4.3.1 Pancreas retrieval  
The organs used for the islet isolation generally are pancreas previously proposed 
and not utilized or excluded for the whole pancreas transplantation. This strategy, 
adopted in order to decrease the competition between the two types of transplantation, 
allows in the case of pancreas for islets isolation the use of organs from donors with 
high BMI or >50 years old. Moreover, with the aim to expand the pool of donors, some 
Figure 1.3 - Essential steps in islet transplantation (Onaca et al., 2007). 
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authors reported positive experience of islet transplantation using donors after cardiac 
death (Saito et al., 2010).  
The harvesting procedure of the gland is similar to the procedure for the whole 
pancreas transplantation, and need the same meticulous attention. After perfusion with 
cold preserving solution, the pancreas is collected paying particular attention not to 
section the pancreatic capsule, event that may impair the enzymatic digestion.  
The pancreas is harvested en bloc with a portion of duodenum and the spleen. After 
procurement the pancreas is kept in cold preservation solution at 4°C, and transported to 
the Islet Isolation Facility. At the moment, the pancreas preservation is obtained thanks 
to a double-layered system: the organ is placed within a superior layer of preservation 
solution and an inferior layer of perfluorocarbons which are constantly oxygenated and 
help maintaining a high oxygen solubility coefficient. This method allows the 
development of a highly oxygenated environment for the pancreas which is of great 
importance for the protection of the islets (Hering et al., 2002). The gland can be kept in 
this solution for several hours although it was reported that the best results were 
achieved when the cold ischemia time was <16 hours (Tsujimura et al., 2004). 
1.4.3.2 Islet isolation  
Human islet isolation remains a challenging process, with only about 50% of optimal 
pancreases achieving transplantable islet yields in the leading isolation centers 
worldwide. The technical hurdles, together with the new stringent regulations 
introduced in most countries regarding human tissue processing, have meant that islet 
isolation is no longer performed in every center. Indeed, a number of “hub and spoke” 
networks have been created worldwide, in which islets are isolated at a central Islet 
Isolation Facility, and isolated islets then transported to different satellite centers for 
infusion into local patients. This model is more cost-effective, and it also enables 
consolidation of islet isolation expertise. 
With regards the technical side of islet isolation, the procedure currently used to 
extract the intact islets of Langerhans while removing the exocrine/acinar tissue is the 
so-called automated method established in 1987 by Ricordi and colleagues. This is 
performed in two main stages: first, the pancreas is broken down by a combination of 
enzymatic digestion and mechanical dissociation, resulting in the islets being released 
from the surrounding tissue and the pancreas being broken down into a liquid digest 
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containing both the islets, and the exocrine and ductal tissue (pancreas digestion). 
Second, the pancreatic digest is subjected to density-gradient purification during which 
the lower density islets are separated (purified) from the other tissue (islet purification).  
Pancreas digestion 
Once retrieved, the pancreas is disinfected with a dilute iodine solution. The 
surrounding fat is removed by careful dissection, making sure that the pancreatic 
capsule is kept intact. The pancreatic duct is then cannulated using a standard 
intravenous cannula. A solution containing commercially available bacterial 
collagenase, derived from Clostridium histolyticum, is perfused through the cannula 
into the pancreatic ductal network, thereby distributing collagenase throughout the 
pancreatic parenchyma. The distended pancreas is then placed in a stainless steel or a 
disposable Ricordi chamber, which is situated within the isolation circuit. The digestion 
process is a combination of enzymatic digestion by collagenase, and mechanical 
dissociation of the pancreas by the manual or automated agitation of the ball 
bearings/marbles within the digestion chamber. Minimal essential media containing 
antibiotics and a number of other required additives are circulated around the circuit 
while digestion proceeds. Digestion is monitored throughout by analysis of fluid 
“biopsies” taken every 3-5 minutes. Each “biopsy” is stained with dithizone, a 
compound that stains the zinc granules within islets red, while leaving exocrine tissue 
unstained. At the point where sufficient freed islets are seen completely devoid of 
exocrine tissue, the isolation circuit is switched to an “open” circuit, and collection of 
the pancreatic digest undertaken. The collected pancreatic digest is centrifuged, and the 
packed cell volume resuspended in University of Wisconsin solution. 
Islet purification 
The pancreatic digest contains both released islets and the broken down exocrine 
tissue. The aim of islet purification is to separate these two different components, 
thereby producing pure islets. This enables the transplanted tissue volume to be kept to 
a minimum. Islet purification is performed by density-gradient centrifugation, which 
makes use of the fact that islets are less dense than their exocrine counterpart. Once the 
islets have been purified, they are counted and assessed for overall purity and viability 
percentages. The exocrine tissue is then discarded, and the islets placed in culture 
media. 
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1.4.3.3 Islet culture  
Previous islet transplant protocols used “fresh” islets immediately after isolation. 
However, the original Edmonton protocol has been modified in several ways so that 
most centers now culture isolated islets for 48 to 72 hours to obtain a cleaner islet 
suspension with less immunogenic and thrombogenic collagen and debris, and 
administer anti-inflammatory therapy peri-transplant (Harlan et al., 2009). A period of 
at least 24 hours of culture is encouraged for a number of reasons: first, there are data to 
suggest that islets benefit from a “recovery” period after the metabolic insults endured 
during islet isolation, before being implanted. Second, the culture step enables the islets 
to be subjected to detailed quality testing before the transplant is performed, including 
tests of islet function, viability and sterility. Third, before the culture step was routinely 
used, the necessity to use “fresh” islets rendered islet transplantation an emergency 
procedure that had to be performed whenever the islets had been isolated. Islet culture 
has enabled this procedure to be planned, benefitting both patient and health care 
resources (Johnson et al., 2012). 
1.4.3.4 Islet transplant procedure  
The islet transplant procedure itself is the culmination of a time-consuming process 
of careful patient selection and detailed patient work-up (fig. 1.4). The immediate post-
transplant management is also critical to ensure optimal islet graft function. 
Islet transplantation is a quite safe procedure, anyway the requirement for long-term 
immunosuppression, which has as well known important side effects, means that this 
treatment is currently reserved for people with the most severe forms of T1DM. This 
limitation is a consequence of the benefit/cost ratio between improvement of the 
glycemic control and the necessity for recipients to be treated with chronic 
immunosuppressive therapy. 
These considerations and the availability of new generation basal insulin and 
sophisticated micro insulin pumps lead the majority of European centers to perform islet 
transplantation almost exclusively in combination with kidney transplant in T1DM 
patients candidate (simultaneous islets-kidney transplant), or just subjected (islet after 
kidney transplant), to a kidney transplantation for end-stage diabetic nephropathy. 
These patients therefore would anyway be treated with immunosuppressive drugs 
(Cavallari et al., 2012).  
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Although a number of anatomical sites have been investigating for hosting the islet 
transplant, nowadays the liver, by islet injection via the portal vein, remains the site 
preferably used in the clinical setting for several reasons: the position of the liver and 
portal vein lend themselves to percutaneous access; the structure of the sinusoids 
prevents islets from flowing straight through the liver and is ideal for islet entrapment; 
the total blood flow within the liver facilitates islet engraftment and maximal function. 
Alternative sites include the spleen, the renal subcapsule, the omental pouch, the 
peritoneum, the skeletal muscle, and the ovary or testis (both immune-privileged sites 
but with practical drawbacks) (Johnson et al., 2012).   
The adequate amount of islets obtained is calculated with respect to the body weight 
of the recipient and resuspended immediately before the intrahepatic transplantation in 
an adequate solution (Cavallari et al., 2012).  
In the face of organ shortage and procedure-related costs, these findings may lead to 
a new paradigm in islet transplantation, where the primary aim is not necessary to 
achieve the same insulin independence as in whole organ transplantation, but to 
improve the glycemic control of the patient through a less invasive procedure. 
Promising fields of research are nowadays focused on increasing the engraftment and 
survival of the islets after transplantation. If these studies will give positive results, it 
will be possible in future to extend the actual indications of the combined kidney-islet 
transplantation procedure.  
Figure 1.4 - The main idea of islet transplantation is to process the donor’s pancreas so as 
to remove the exocrine tissue and isolate the portion of the gland responsible for the 
endocrine hormone secretion. The medical team infuses the isolated islets into the portal 
vein. The islets are transported by the bloodstream into the liver, where they lodge, starting 
to produce the right amount of insulin to regulate the blood sugar (Naftanel et al., 2004). 
1 - Introduction 
 
23 
 
1.4.4 Etiologies of graft dysfunction  
Multiple reasons have been cited as underlying etiologies of graft failure (fig. 1.5). 
The period surrounding transplantation is marked by a rapid loss of approximately 50-
70% of donor islets (Korsgren et al., 2005). This large-scale islet loss is partly caused 
by the quality of donor pancreata as well as the isolation process itself, which includes 
enzymatic digestion, cold-storage time, and exposure to hypoxia during isolation and 
culture (Nanji et al., 2006). These combined stresses generate inflammatory cytokines 
and initiate pro-apoptotic NF-κB, mitogen-activated kinase, and poly(ADP-ribose) 
polymerase stress pathways before transplantation has even occurred (Abdelli et al., 
2004).  
Another major culprit, detrimental to islet survival, is the innate immune system, 
which launches a large-scale inflammatory reaction, initiating massive β-cell death 
immediately after intravascular infusion (Korsgren et al., 2005). This instant blood-
mediated inflammatory reaction (IBMIR) occurs secondary to the brisk activation of 
coagulation and complement cascades, which are triggered by exposure of tissue factor 
(TF) expressed by islets to human blood. 
 
 
 Figure 1.5 - Factors limiting islet graft function and/or survival (Harlan et al., 2009). 
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Although the innate immune response causes early β-cell death, long-term 
deterioration in graft function is also related to allo- and autoimmunity (Ryan et al., 
2005). Similar to solid organ transplants, islet grafts are susceptible to the development 
of allograft rejection via sensitization to alloantigens presented by antigen presenting 
cells and subsequent activation of a T-cell-dependent immune response. The rejection 
process can be mitigated by immunosuppressants, but once drug levels are decreased, 
allosensitization occurs (Cardani et al., 2007).  
Given that T1DM is an autoimmune disease, recurrent autoimmune destruction 
involving donor islet antigens may also play a role in graft failure.  
 
 
 
 
 
 
Another hurdle that has emerged as a limitation in graft viability and function is the 
development of an optimal vascular network (Menger et al., 2001). Normal pancreatic 
islets are microorgans, which contain a dense capillary network, approximately 10 times 
higher than that of the surrounding exocrine tissue. Although the islet cells comprises 
only 1% to 2% of the total pancreatic mass, islets receive 5% to 10% of the pancreatic 
blood flow (Lifson et al., 1985). The blood vessels within the islets are lined with 
fenestrated endothelial cells (ECs), suggesting an increased importance of perfusion and 
sensitivity to hypoxia (Lau et al., 2009). Unfortunately, this network is interrupted 
during the islet isolation process, and as a consequence β-cells become necrotic in 
culture, starting from the core region of larger islet (fig. 1.6). Transplanted islet oxygen, 
nutrient supply, and exposure to intraislet paracrine signaling are limited by rate of 
neovascularization and alterations in the vascular development that differ compared to 
the vascular networks seen in native islets (Carlsson, 2011). The reestablishment of an 
Figure 1.6 - (a) Schematic drawing of oxygen supply to pancreatic islets of different sizes 
during islet culture and early post-transplantation. Darker colour indicates less 
oxygenation. (b) Micrograph of islet with developed central necrosis due to poor 
oxygenation of the islet core (Lau et al., 2009). 
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adequate blood flow to transplanted islets depends on an angiogenesis process that 
requires several days, and, even when complete (generally by 10-14 days after 
transplant), is suboptimal.  
The site of transplantation may also have important implications. Concerning the 
liver, often the standard organ of choice, one should consider the drawbacks of the 
portal vein, including the IBMIR, higher levels of toxic immunosuppressants in the 
portal circulation, periportal steatosis, and an inability to routinely biopsy the 
transplanted islets because they are dispersed within the liver (Harlan et al., 2009).  
1.5 Adult stem cells 
Several studies have revealed that a population of adult stem cells and supporting 
cells reside in most of adult mammalian tissues/organs, including bone marrow, heart, 
kidneys, brain, skin, eyes, gastrointestinal tract, liver, pancreas, lungs, breast, ovaries, 
prostate, and testis. In general adult stem cells are thought to be localized in specific 
areas of each tissue, within a specialized microenvironment called “stem cell niche”, 
consisting of the neighboring cells such as fibroblasts, endothelial cells and/or stromal 
components that tightly regulate their functions through direct interactions and release 
of specific soluble factors (Li et al., 2005).  
All the multipotent or bipotent adult stem cell types display a long-term self-
renewing capacity and in appropriate conditions (including the onset of an intense 
injury) give rise to all the mature and specialized cell types of distinct lineages in the 
tissues/organs from which they originate, or sometimes even to cell lineages of distant 
sites. Despite some adult stem/progenitor cells, found in bone marrow, skin and 
gastrointestinal tract, usually show a rapid turnover, to replenish the cells lost along 
lifespan other adult stem cell types remain quiescent and rarely divide in normal 
conditions, undergoing a sustained proliferation only after tissue injury (Mimeault et al., 
2008).  
1.5.1 Mesenchymal stem cells  
Mesenchymal stem cells (MSCs) are multipotent progenitor cells found in 
perivascular spaces of many adult tissues. They have been known since 15-20 years, 
and were identified for the first time in bone marrow. To isolate human MSCs, bone 
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marrow aspirate is harvested from the iliac crest and processed. Bone marrow-MSCs 
(BM-MSCs) are relatively easy to expand in culture under conditions in which they 
retain some of their potential to differentiate into multiple cell lineage that include 
osteoblasts, adipocytes, chondrocytes, myoblasts, and early progenitors of neural cells. 
They are enriched and expanded in presence of fetal calf serum by their tight adherence 
to plastic tissue culture dishes. A culture of human MSCs, unlike murine cells, can 
become free of hematopoietic precursors after one or two passages, and can be 
extensively expanded before reaching senescence (Sekiya et al., 2002). 
 
                 
 
Human MSCs in culture appear fibroblast-like and homogeneous in size and 
morphology (fig. 1.7) starting from the second passage. MSCs haven’t a unique peculiar 
marker but, in recent years, a panel of cell surface antigens emerged to characterize 
them. Negative and positive selection markers of MSCs have been so defined: MSCs do 
not express CD14, CD34, CD45, CD117 (cKit), HLA class I, and HLA-DR antigens, 
whereas they are positive for CD13, CD29, CD44, CD73, CD90, CD105, and CD166. 
These markers are located in the cell membrane of the MSCs, and antibodies are readily 
available for FACS analysis and sorting (Maurer, 2011). 
 
hMSC surface markers 
Figure 1.7 - Culture of human MSCs (Pittenger et al., 2004). 
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1.5.2 Alternative sources of hMSCs 
Bone marrow represents the main source of MSCs for both experimental and clinical 
studies. However, the number of bone marrow MSCs significantly decreases with age, 
which makes necessary the search for adequate alternative sources for autologous and 
allogeneic use. Most attention should be paid to tissue containing cells with higher 
proliferative potency, capability of differentiation, and lower risk of contamination. In 
2003 scientists saw in the umbilical cord/placenta vessels the presence of MSCs, in 
particular Romanov and colleagues found a type of cell ascribable to MSCs for the 
presence of surface markers, morphology and the possibility to differentiate into 
adipocytes and osteoblasts. Other research groups have found multipotent stem cells in 
tissues like mobilized peripheral blood, umbilical cord blood and fetal membranes 
(Ventura et al., 2007), deciduous teeth, umbilical cord mesenchyme (Wharton’s jelly, 
WJ), and adipose tissue.  
1.5.2.1 Adipose-derived stem cells  
Adipose tissue derives from embryonic mesoderm, and has emerged as a promising 
source of adult stem cells with regenerative capacity. As mesenchymal stem cells, the 
isolated cells are capable to differentiate into mesodermal and potentially ectodermal 
and endodermal lineages, but again the ability to differentiate into all lineages is 
somewhat controversial (Mizuno et al., 2012). These stem cells have been variously 
termed, anyway a recent consensus was reached by investigators at the 2004 conference 
of International Fat Applied Technology Society, which has settled on the term 
“adipose-derived stem cells” (ASCs).  
Abundant numbers of ASCs can be derived from lipoaspirate, the waste product of 
liposuction surgery. Processing 300 ml of lipoaspirate routinely yields between 1 x 10
7
 
and 6 x 10
8
 ASCs with >90% cell viability. The yield compares favourably with a bone 
marrow aspirate. Compared with BM-MSCs, ASCs are more easily cultured and grow 
more rapidly. They can also be cultured for longer than BM-MSCs before becoming 
senescent. All of these qualities make ASCs a useful source of mesenchymal stem cells 
(Locke et al., 2009). 
Adipose stem cells can be found in any type of adipose tissue, including 
subcutaneous and omental fat. In recent years obesity has become a huge problem in the 
Western world, and the number of liposuctions has increased significantly. Liposuction 
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is considered a safe and well-tolerated procedure, with a complication rate of around 
0.1%. Research shows that 98-100% of the adipose cells in the lipoaspirate are viable. 
Given the safety and popularity of liposuction, lipoaspirate seems an ideal source of 
ASCs, and a safe autologous cell source for clinical use. 
ASCs are obtained from the adipose stromal vascular fraction (SVF), a population of 
cells harvested after enzymatic dissociation of adipose depots followed by density 
separation from adipocytes. After standard condition cells develop a fibroblast-like 
morphology. 
A comparative analysis of MSCs obtained from bone marrow, adipose tissue, and 
umbilical cord clearly showed that ASCs were not different regarding morphology, 
immune phenotype, success rate of isolation, colony frequency, and differentiation 
capacity. However, some characteristics, such as the colony frequency and the 
maintenance of proliferating ability in culture, seem even to be superior in ASCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There isn’t a clear discrimination between ASCs (fibroblast-like stem cells) and 
fibroblasts, but observing the set of criteria to define human MSCs (i.e. plastic 
adherence under standard culture condition, ability for differentiation, expression of 
CD73, CD90, CD105, lack of expression of c-Kit, CD14, CD11b, CD34, CD45, CD79α 
Table 1.3 - Molecular phenotype of adipose-derived 
stromal cells (modified from Schaffler et al., 2007).  
ASC-positive cellular 
markers and genes 
ASC-negative cellular 
markers and genes 
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and the known ASC expression profile of surface markers in table 1.3) we could support 
the hypothesis that ASCs and BM-MSCs have originated from identical precursor cells 
(Schäffler et al., 2007) . 
ASCs, similarly to BM-MSCs, have the potential to differentiate into bone, cartilage, 
tendons, skeletal muscle, and fat when cultivated under lineage-specific conditions. 
Moreover ASCs demonstrated to have the potential for “cross differentiation” in 
neurons, endocrine pancreatic cells, hepatocytes, endothelial cells and cardiomyocytes 
(cells of non-mesodermal origins) (table 1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.2.2 Lipogems: a highly enriched stromal cell fat-derivative 
Regulation of hMSC usage requires that extensively manipulated cells for clinical 
use have to be manufactured in accordance with current Good Manufacturing Practice 
(cGMP) guidelines. However, these restrictions are not applied in case of minimal 
manipulation [Regulation (EC) No 1394/2007 of the European Parliament and of the 
Council]. Therefore, developing devices and strategies encompassing a minimal 
manipulation to make available a ready-to-use, autologous fat product would have 
obvious biomedical and clinical relevance to translate cell therapy promises into a 
clinical practice. Akin to this perspective, Lipogems is an innovative system that 
isolates a highly enriched ASC-containing product from minimal amounts of 
lipoaspirates (Tremolada et al., 2010). Lipogems simply uses mild mechanical forces, 
avoiding the use of enzymes, additives, and other inherent manipulation (i.e. separative 
centrifugation and subfractional harvesting). The clusters of fat obtained from a 
liposuction is reduced by using filters and spheres, contained in a completely closed 
Table 1.4 - Experimentally used factors triggering the differentiation of adipose-derived stem 
cells (Schaffler et al., 2007).  
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system, designed for total washout of oil and blood. Oil removal also makes 
inflammation negligible while increasing the chances for cell engraftment. The isolation 
is really fast, taking 15-20 minutes for each sample.  
The Lipogems product is very fluid and exhibits a number of clinically relevant 
features: 
1. The Lipogems product can be reinjected immediately into the donor patient itself. 
This autologous strategy is safe, it does not require stem cell expansion or 
manipulation, and therefore it is not subjected to any of the regulatory restriction 
imposed by the cGMP guidelines. 
2. Differently from unprocessed lipoaspirate, the non-expanded Lipogems product has 
a remarkably preserved vascular/stromal architecture, and can be stored frozen 
without losing neither the architecture nor the ability to release highly functional 
and viable hASCs after thawing. 
3. Lipogems is highly enriched in MSCs and pericytes, with a low amount of 
hematopoietic-like elements (Bianchi et al., 2012). 
4. When placed in cell culture medium, the Lipogems product spontaneously releases 
its stem cell pool, with subsequent attachment of a highly homogeneous hMSC 
population to the plastic dish. These cells can be mechanically harvested and pooled 
prior to any cell expansion, being equivalent to a “time zero, non-proliferating 
condition” that does not involve any substantial manipulation. 
1.5.3 MSC immunogenicity 
Immunomodulatory and anti-inflammatory properties are increasingly viewed as key 
properties of MSCs isolated from multiple organ sources, which can extend (or even 
supersede) their importance as versatile multipotent cells. While the differentiation 
properties of MSCs seem to be dependent on microenvironmental clues in vivo, the 
immunomodulatory effects appear to be rather intrinsic.  
Many reports have evidenced, first in vitro and then in vivo, the ability of MSCs to 
express molecules that can interact with both innate and adaptive immunity processes, 
in a cell contact-mediated fashion and/or in experimental settings where cell-cell 
interaction is precluded, thus suggesting the importance of soluble factors in mediating 
these processes (Vija et al., 2009). 
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1.5.3.1 In vitro evidence of immunomodulation 
Adult human MSCs express intermediate levels of major histocompatibility complex 
(MHC) class I molecules on their cell surface, but not MHC class II (HLA-DR), 
properties that make them hypoimmunogenic and immunoprivileged, allowing 
transplantation across allogeneic barriers. In addition MSCs can synthesize trophic 
mediators such as growth factors and cytokines, involved in cell signaling and 
modulation of immune response. Recent studies demonstrated that the secretion of key 
soluble factors is not constitutive, but is often a consequence of cross-talk between 
MSCs and T lymphocytes, the latter being able to trigger this de novo expression (Nauta 
et al., 2007). 
In vitro experiments show that MSCs can modulate the immunological activity of 
different cell populations, the most important being their inhibitory effect on T-cell 
proliferation and dendritic cell (DC) differentiation. MSCs are also able to inhibit 
proliferation of CD4
+
 helper and CD8
+
 cytotoxic T-cells, as well as memory and naïve 
T-cells, B-cells and Natural Killer (NK) cells (fig. 1.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 - Plausible mechanisms by which MSCs regulate immune responses: reducing 
the generation and differentiation of DCs (1); increasing the percentage of regulatory T-cells 
through production of cytokines (2); engaging in cell-to-cell contact with T-cells and ECs 
(3,4); suppressing effector T-cells through various growth factors (5); acting through down-
regulation of immunoglobulin production by B-cells (6); up-regulating MHC II on MSCs 
thus leading to down-regulation of NK cell cytotoxicity and proliferation (7) (Abdi et al., 
2008). 
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It has been reported that MSCs can modulate T-cell proliferation thanks to their low 
expression of costimulatory molecules including B7-1 (CD80), B7-2 (CD86), or CD40, 
and the absence of MHC-II. This mechanism may necessitate an initial contact phase as 
well as specific mediators produced by MSCs, such as transforming growth factor-β 
(TGF-β), prostaglandin E2 (PGE2), hepatocyte growth factor (HGF), interleukin-10 
(IL-10), and indoleamine 2,3-deoxygenase (IDO).  
MSCs may also determine T-cell arrest in G0-G1 phase by inhibition of cyclin D2 
expression resulting in T-cell anergy, and stimulate the production of CD8
+
 regulatory 
T-cells (Tregs), that inhibit allogeneic lymphocyte proliferation (Vija et al., 2009).  
MSCs are able to interact with dendritic cells, not only inhibiting differentiation of 
monocytes into DCs but also inhibiting DC maturation, giving rise to immature DCs 
that could subsequently render T-cells anergic. MSCs have also been shown to alter the 
cytokine secretion profile of DCs toward up-regulation of regulatory cytokines such as 
IL-10 and down-regulation of inflammatory cytokines such as interferon- γ (IFN-γ), IL-
12, and tumor necrosis factor TNF-α, inducing a more anti-inflammatory or tolerant DC 
phenotype (Abdi et al., 2008).  
Concerning B lymphocytes, MSCs can inhibit their proliferation and activation in a 
dose-dependent manner and modulate their differentiation, antibody production and 
chemotactic abilities (Corcione et al., 2006). 
Lastly, MSCs could suppress proliferation of NK cells, decrease the secretion of 
IFN-γ by IL-2 stimulated NK cells, and affect cytotoxicity against HLA class I-
expressing targets. 
1.5.3.2 Tolerance induction 
Tolerance to self-antigens is a process of fundamental importance for the correct 
development of the human immune system. Peripheral tolerance mechanisms act 
together with central tolerance, based on the role of Treg cells. A key molecule in which 
a tolerance-induction role has been demonstrated is HLA-G (a non-classical MHC I), 
which was first characterized in trophoblast cells, where it mediates tolerance towards 
the semi-allogeneic embryo. HLA-G has been found to be expressed in different MSC 
populations, such as BM-MSCs and WJ-MSCs. This molecule has been directly linked 
to the tolerogenic ability of MSCs, e.g. inducing the expansion of CD4
+
CD25
+
FoxP3
+
 
Tregs which would contribute to the suppression of effector responses to alloantigens. 
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HLA-G would act both in its membrane-bound isoform, implicating direct cell-cell 
contact, or by its shedding from the cellular surface (the soluble isoform is defined as 
HLA-G5).  
In a recent paper, Gonzalez and colleagues demonstrated that the beneficial action of 
ASCs on experimental rheumatoid arthritis was due to the generation and activation of 
Treg cells.  
Taken together, these data indicate that one of the great expectations linked to the use 
of MSCs may reside in their ability to successfully engraft, evading an immune 
response and inducing peripheral host tolerance (Anzalone et al., 2011). 
1.5.4 Vasculogenesis and MSCs 
1.5.4.1 Vasculogenic differentiation  
There are some evidences of the existence of an heterogeneous population in MSCs, 
that means the presence of undefined subfractions of stem cell populations with a great 
differentiation potential. There is a subpopulation positive for Flk-1/KDR (kinase insert 
domain receptor, a major receptors for vascular endothelial growth factor, VEGF) and 
negative for CD31 and CD34, which can differentiate into endothelial cells.  
 
 
 
 
 
Figure 1.9 - Morphological changes during endothelial differentiation of ASCs. 
(A) 0 h; (B) 12 h; (C) 24 h; (D,E) 48 h (Cao et al., 2005). 
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Cao and colleagues exploited a method which allows to isolate and expand an ASC 
subset Flk-1⁺CD31-CD34- able to differentiate into ECs. The cells were cultured into 
functional ECs in vitro, with 50 ng/ml VEGF, 10 ng/ml bFGF (basic fibroblast growth 
factor) on Matrigel coated coverslips. Light microscopy observation over a period of 48 
hours showed that vascular network was formed by ASCs after incubation with 
endothelial differentiation medium (fig. 1.9). PCR and immunocitochemistry confirmed 
the presence of EC markers including CD31 (PECAM-1), CD34, CD144 (VE-
cadherin), and endothelial nitric oxide synthase (eNOS) (Cao et al., 2005). Positive 
results were obtained in in vivo mouse limb ischaemia model, where injected human 
ASCs were detected in the injury site. 
1.5.4.2 Secretion of paracrine factors 
As MSCs enter and progress toward an end-stage phenotype, the quantity and array 
of secreted bioactive factors changes as the descendants of MSCs enter new lineage 
stages. The pattern and quantity of such secreted factors is well known to feedback on 
the cell itself and govern both its functional status and physiology. Of course functional 
paracrine and autocrine secretion of factors can have profound impact on local cellular 
dynamics.  
The effects of MSC-secreted bioactive molecules can be either direct or indirect or 
even both: direct by causing intracellular signaling, or indirect by causing another cell 
in the vicinity to secrete the functionally active agent. As shown in figure 1.10, MSCs 
can have two distinct functions: they can provide replacement units for expired cells in 
mesenchymal tissues, and have trophic effects on cells in their vicinity without 
generating newly differentiated mesenchymal phenotypes and, thus, also influence the 
regeneration of cells or tissues by purely a bioactive factor effect. 
An important characteristic that makes ASCs a good alternative in cell therapy is the 
participation in endocrine processes by secreting cytokines and growth factors (Kilroy et 
al., 2007). ASCs secrete high levels of epidermal growth factor (EGF), VEGF, bFGF, 
keratinocyte growth factor (KGF), platelet-derived growth factor (PDGF), HGF, TGF-β, 
insulin-like growth factor (IGF), and brain-derived neurotrophic factor (BDNF). They 
also secrete cytokines such as Flt-3 ligand, G-CSF, granulocyte-macrophage colony-
stimulating factor (GM-CSF), M-CSF, IL-6, IL-7, IL-8, IL-11, IL-12, LIF, and TNF-α. 
This secretion of paracrine factors by the adipose tissue likely contributes to the 
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elevated levels of these cytokines in cases of obesity. Worthy to note, these angiogenic 
and anti-apoptotic growth factors are secreted in bioactive levels by ASCs and their 
secretion increases significantly under hypoxic conditions (Rehman et al., 2004; Lee et 
al., 2009).  
 
                     
  
 
HGF is possibly the main angiogenic factor secreted by ASCs, playing a central role 
in the paracrine effects on ASCs. Its suppression has been shown to impair the 
angiogenic and regenerative effects of ASCs in ischemic tissues. Silencing HGF 
reduces the ability of ASCs to promote EC proliferation and inhibits the pro-angiogenic 
effects of HGF in vitro (Cai et al., 2007).  
1.5.5 Stem cells as a tool to address limitations of islet transplants  
Recent advances in the field of stem cell research have stimulated significant interest 
in the potential role that both multipotent (adult), pluripotent (embryonic), and induced 
pluripotent stem (iPS) cells could play in the replacement of islets in patients with 
T1DM. The unique properties of different postnatal or adult stem cell populations offer 
valuable supportive functions that appear to enhance graft function and survival. In 
addition to a potential role as companion cells during transplantation, pluripotent or 
embryonic stem cells (ESCs) present a potential alternative for the generation of insulin 
producing cells (IPCs). The use of adult stem cell populations has also emerged as a 
Figure 1.10 - Schema representing the dual role of MSCs: abilities in tissue 
regeneration and repair, and trophic secretion of bioactive factors that mediate 
the functional tissue outcomes (Caplan et al., 2006).  
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potential source of IPCs, and these cells can be directed down a pancreatic and 
endocrine lineage of development. 
1.5.5.1 Generation of insulin-producing cells  
Exploration into the possibility of reprogramming human somatic cells into 
embryonic-like cells has also resulted in promising outcomes. Although autoimmunity 
would still present a challenge, this prospect is especially enticing given that patient-
specific β-cells could be generated, circumventing the need for immunosuppression to 
prevent rejection. Social and ethical objections to use of human ESCs would also be 
avoided. These iPS cells could ideally be directed down a pancreatic endocrine 
developmental program and then be used to obtain insulin producing cells (IPCs). While 
this field has not yet advanced as far as the hESC field, several studies utilizing these 
protocols show the generation of IPCs that express insulin and some other markers of 
mature β-cells (Zhang et al., 2009; Tateishi et al., 2008). Despite some promising 
results of investigations using hESCs and iPS cells to generate IPCs, several other 
limitations exist that are unique to these cell populations. In addition to the incomplete 
differentiation, the recombinant proteins required for the process are extremely 
expensive. Current research is exploring chemical compounds that could replace these 
proteins in protocols, while providing more easily regulated and efficient processes of 
guiding differentiation (Lin et al., 2009). Safety concerns have also arisen regarding 
teratoma formation from undifferentiated cells (Fujikawa et al., 2005). Some have 
explored the possibility of forcing adult stem cells that could otherwise be used as 
supportive cells in transplantation strategies towards a β-cell lineage in vitro. These 
cells may then be able to directly contribute to islet graft success through differentiation 
into IPCs (Dor et al., 2004).  
Conflicting in vivo evidence exists for IPC development from MSCs. In mice 
transplanted with islets and BM-MSCs, an increase in pancreatic and duodenal 
homeobox gene (PDX-1) positive cells was noted in bone marrow cells. Other in vivo 
studies have had negative results, with no evidence of MSC-derived β-cells observed in 
murine pancreatic injury or transplantation models, despite improved islet graft function 
(Sordi et al., 2010). These studies reflect that the majority of MSC effect on β-cell 
regeneration likely occurs through augmentation of endogenous cell survival or 
regeneration. 
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Similar to BM-MSCs, ASCs are capable of differentiation into primitive IPCs in 
vitro under certain culture conditions (Timper et al., 2006). Analogous to MSCs, much 
of the evidence regarding ASC effects on islet replacement points to their role as 
supportive cells. 
1.5.5.2 Stem cells as companion cells  
1.5.5.2.1 Mesenchymal stem cells 
Among the most studied of adult stem cells as companion or supportive cells for islet 
transplantation are MSCs (fig. 1.11). The multipotent, immunomodulatory, and 
regenerative properties of these cells have inspired applications in models of tissue 
injury and immune diseases, ranging from increased neurogenesis in rats to inhibition of 
pro-inflammatory cytokines in murine acute lung injury models (Uccelli et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In preclinical studies, cotransplantation of islets and MSCs has emerged as a 
promising tool to improve graft survival. Early studies focused on the effects of BM-
MSCs and the benefits of this cell population on transplanted islet function have been 
demonstrated repeatedly through in vivo experiments in rodents and primates. 
Cotransplantation with syngeneic MSCs results in a lower β-cell requirement for 
Differentiation into 
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(β-cell replacement) 
Immunomodulatory 
capabilities 
Neovascularization, 
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vascular network 
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Figure 1.11 - Role of mesenchymal stem cells in islet transplantation 
(modified from Harlan et al., 2009). 
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normoglycemia, with observed improvements in glucose tolerance and prolonged 
viability of allogeneic islet transplants in mice (Ito et al., 2010; Figliuzzi et al., 2009). 
In diabetic cynomolgus monkeys at 1 month after transplantation, the combination of 
MSCs with islets confers prolonged graft function with significantly increased C-
peptide levels compared to islets transplanted with nonspecific bone marrow cells 
(Berman et al., 2010). Because of their adhesive properties, MSCs have also been 
shown to coat islets in a coculture system. This characteristic provides a potential model 
for transplantation that may improve interactions between the cell types after 
engraftment (Duprez et al., 2011).  
Numerous studies have been undertaken to investigate the mechanisms behind the 
beneficial effects of BM-MSCs. One important contribution of MSCs appears to be 
related to their immunomodulatory capabilities. MSC administration in mice with 
allogeneic islet grafts was associated with decreased delayed-type hypersensitivity. 
Additional MSC dosing was associated with reversal of acute rejection of allogeneic 
transplants in monkeys (Berman et al., 2010). These properties are mediated via 
production of multiple factors that collectively act to suppress T-cell proliferation and 
function, DC maturation, and NK-cell proliferation. MSC-derived factors act on these 
immune cells to decrease secretion of pro-inflammatory cytokines including INF-γ, 
GM-CSF, TNF-α, and monocyte chemoattractant protein-1 (Ding et al., 2009; Longoni 
et al., 2010). MSCs also act to induce regulatory T-cells and the generation of anti-
inflammatory cytokines like IL-10, modulate neutrophil function, and B-cell function 
and differentiation (Aggarwal et al., 2005). Collectively, these effects create a shift 
away from antigen-specific cytotoxicity and inflammation.  
Another component to the advantageous effects of MSCs is their contribution to 
establishing a vascular network for new islet grafts. Compared to islets transplanted 
alone, multiple studies have demonstrated that mice transplanted with BM-MSCs 
combined with islets had a significant increase in periislet vessel number, with a higher 
capillary to β-cell ratio observed post-operatively. In cotransplantation models, the 
development of new vessels in hybrid grafts was observed earlier (Sakata et al., 2010). 
This earlier and more pronounced increase in capillary density seems to occur 
secondary to secretion of multiple pro-angiogenic factors, including VEGF, IL-6, IL-8, 
HGF, TGF-β, and PDGF (Golocheikine et al., 2010). MSC secretion of matrix 
metalloproteinases is also thought to initiate degradation of the preexisting extracellular 
matrix (ECM), allowing endothelial cells to migrate into islets.  
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In addition to pro-angiogenic effects, MSCs also have potent anti-apoptotic effects 
that protect islets from the hypoxia and inflammatory destruction which occurs as a 
result of the isolation and transplantation process. In an in vitro model of islet hypoxia 
and reoxygenation, rat islets cocultured with BM-MSCs had increased expression of 
protective hypoxia-induced genes, along with decreased apoptotic rates, and improved 
glucose-stimulated insulin secretion when compared to islets cultured alone (Lu et al., 
2010). Cocultured islets also had an increased ATP/ADP ratio leading to improved 
glucose-stimulated insulin release (Park et al., 2010; Xu et al., 2008). In vivo benefits of 
these cells on early islet death from the isolation process are demonstrated by improved 
blood glucose values in diabetic mice receiving a marginal mass of human islets that 
were cultured in MSC media for 48 hours before transplantation. This improvement was 
noted when compared to results obtained from transplantation of islets that had 
undergone more typical isolation procedures (Park et al., 2010). 
Many of the effects of MSCs appear to be mediated via secretion of paracrine 
factors, including HGF, TGF-β, IL-6, VEGF, and PDGF. The importance of this 
influence is supported by a decrease in benefits on islet survival and vessel development 
observed when human islets are cocultured with bone marrow cells and antibodies that 
selectively deplete these paracrine factors. Direct cell contact between the MSCs and 
islets may also play a role as immunomodulatory effects and IL-10 production are 
decreased in vitro when islets are separated from MSCs by a permeable membrane. 
Concurrent transplantation of islets with MSCs also has advantageous effects on islet 
remodeling and structure that may lead to improved insulin secretion as well as 
improved intraislet paracrine communication between β-cells and other islet endocrine 
cells (Kelly et al., 2011). Immunostaining reveals in mice that islets transplanted with 
MSCs develop graft morphology characteristic of native islet architecture, versus a 
more diffuse distribution of α-cells and δ-cells in grafts containing only islets (Rackham 
et al., 2011). 
1.5.5.2.2 Adipose-derived stem cells 
While ASCs are functionally similar to BM-MSCs, they are more easily accessible 
with minimal risk to the patient. Adipose also yields a greater number of stem cells per 
gram of tissue than bone marrow (Nakao et al., 2010). This accessibility is especially 
attractive as patients could easily provide their own populations of cells. 
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ASCs exhibit a number of potential characteristics and effects that are similar to 
MSCs and benefit islet grafts comparably. Combined transplantation of ASCs with a 
marginal islet mass resulted in prolonged graft survival and glucose tolerance similar to 
that observed when using significantly higher numbers of islets. Hybrid grafts had a 
well-preserved islet structure compared to those transplanted with islets alone. These 
hybrid islets also had decreased presence of CD4
+
 and CD8
+
 cells, reflecting an anti-
inflammatory effect (Ohmura et al., 2010).  
While research into the application of ASCs to diabetic models is ongoing, ASCs 
have been studied in several other injury and disease models. Studies in mice with 
proximal femoral artery ligation and subsequent hind limb ischemia have demonstrated 
the pro-angiogenic influence of ASC administration (Mi et al., 2006). In vitro studies 
suggest the etiology is a combination of differentiation and direct incorporation of 
ASCs into vascular structures combined with secretion of angiogenic and anti-apoptotic 
growth factors (Traktuev et al., 2008). These specifically include VEGF, HGF, bFGF, 
GM-CSF, and TGF-β (Rehman et al., 2004). ASC-hybrid grafts demonstrate an 
increased presence of ECs, which appear to be differentiated from ASCs. 
1.5.5.2.3 Endothelial progenitor cells  
Possible benefits on vasculogenesis have generated interest in endothelial progenitor 
cells, which promote angiogenesis at sites of hypoxia or injury and can be obtained 
from bone marrow, cord blood, vessel walls, or peripheral blood. The use of EPCs in 
ischemic injury models has previously been undertaken (Botta et al., 2004).  
Concerning the use of EPCs for therapeutic neovascularization, we have to consider 
that EPCs in T1DM patients are dysfunctional, and their dysfunction may contribute to 
the pathogenesis of vascular complications (Loomans et al., 2004). 
Generation of a more stable vascular network has been achieved by cotransplantation 
of endothelial cells with ASCs. In this context, ASCs are able to function similarly to 
pericytes, which are cells that line vessel walls and support vasculature. This role is 
supported by frequent ASC expression of pericyte surface markers and the 
periendothelial location of ASCs in adipose tissue in vivo. Through paracrine 
interaction, ECs promote mitosis and chemoattraction of ASCs, while ASCs promote 
EC survival and migration (Traktuev et al., 2008).  
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1.5.5.3 Human clinical trials  
Although no clinical human trials have been published that employ stem cells in islet 
transplantation strategies, they are beginning to be employed in other ways.  
Recently, patients with T1DM whose serum lymphocytes were “educated” by 
multipotent human cord blood stem cells demonstrated a progressive improvement in 
fasting and stimulated C-peptide levels up to 40 weeks after treatment. “Education” was 
performed by removing the cells from peripheral blood and returning them to the 
circulation after stem cell exposure. Patients receiving this novel treatment exhibited a 
significant increase in regulatory T-cells and TGF-β1, reflecting immune modulation as 
an explanation for the improved β-cell function (Zhao et al., 2012). Even with clear 
differences in the treatment approach, these results provide promise for a future role of 
stem cells in islet transplants for T1DM in humans.  
Despite the lack of published human clinical trials, a search of registered clinical 
trials (http://clinicaltrials.gov/) revealed about fifteen active studies involving stem cell 
treatments for T1DM. Thirteen studies involved infusion of stem cells (mostly 
autologous MSCs), while one study used a stem cell “educator” as outlined above. Only 
one study planned to evaluate cotransplantation of islets with MSCs. The trials listed 
appear to be of varying quality, and many factors regarding the administration of these 
cells will need to be carefully and rigorously studied. 
1.6 Molecules with differentiating logic  
In eukaryotes, many fundamental biological phenomena, such as transcription, 
replication and DNA repair, involve the interaction of factors with DNA sequences. 
Most of these interactions occur in the context of chromatin environment. Transcription 
factors bind DNA and recruit cofactors that introduce covalent changes in chromatin, 
including DNA methylation and histone modifications (acetylation, methylation, 
phosphorylation). These so-called epigenetic changes have profound effects on gene 
expression, both in physiological and pathological processes (e.g. differentiation and 
cancer).   
The possibility of chemically modifying a gene program, without the aid of gene 
transfer technology, has become more and more interesting as well as real. Targeting 
stem cell fate at the level of gene expression could represent a potentially powerful 
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therapeutic approach to afford a high-throughput of vascular lineage commitment and 
paracrine secretion of trophic factors.  
The current logics in chemical manipulation of stem cell fate for tissue repair are to 
apply single powerful natural or synthetic factors to trigger and/or enhance the onset of 
phenotypic processes. However, stem cell fate is controlled by a complex interplay 
between cell signaling, the establishment of multifaceted transcriptional motifs, the 
temporal and spatial organization of chromatin in loops and domains, and the ability to 
“perceive” the fine architecture and the composition of the extracellular matrix (Ventura 
et al., 2008).  
Based on the above, it’s interesting to design strategies which utilize natural 
occurring molecules (alone or in combinatorial treatment) to induce specific 
commitments and the secretion of trophic mediators of tissue repair.  
1.6.1 Hyaluronic acid (HA) 
Hyaluronic acid (or Hyaluronan, HA), an important constituent of the ECM, is a 
glycosaminoglycan composed of repeating disaccharide units of D-glucuronic acid and 
N-acetyl-D-glucosamine (fig. 1.12). In the cell, hyaluronan synthase enzymes (Has1, 
Has2 and Has3), localized in the plasmatic membrane, synthesize this linear, high 
molecular weight polymer in which the number of repeating disaccharide units can 
reach 10,000 or more and a molecular mass of about 4 million of Daltons (each 
disaccharide unit is about 400 Da).  
 
 
 
This polysaccharide, ubiquitously distributed in the ECM of almost all animal 
tissues, regulates cellular events such as cell proliferation and locomotion that are 
required for a variety of biological processes.  
Figure 1.12 - Hyaluronan basic structure: the repeating 
disaccharide unit. 
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HA has an extraordinarily high rate of turnover, and at the cellular level it is 
considered to be degraded progressively by a series of enzymatic reactions mediated by 
hyaladherins that generate polymers of decreasing sizes. 
Hyaluronic acid functions differently depending on its molecular size and 
concentration. High molecular weight HA or native HA (about 10
7
 Da) plays a 
structural role and inhibits inflammation, immune response and angiogenesis (inhibits 
EC proliferation and disrupts confluent endothelial monolayers). Consistent with these 
findings are the observations in chick embryo limb buds that avascular regions are rich 
in high molecular weight HA, and that expression of this form of hyaluronic acid in 
normally vascular areas results in decreased vascularity. On the other hand, low 
molecular weight HA (HA fragments in the 6-20 kDa size range) stimulates 
inflammation and immune response, and promote angiogenesis in vivo. HA fragments 
have also been demonstrated to induce proliferation, migration and capillary tube 
formation in cultured ECs in vitro (Wang et al., 2011).  
HA appears to exert its biological effects through binding interactions with specific 
cell-associated receptors. A number of hyaluronan-binding proteins have been 
identified, and two molecularly distinct cell-surface receptors for hyaluronan have been 
characterized, namely CD44 and RHAMM (receptor for HA-mediated motility). 
Although several other binding interactions for CD44 and RHAMM have been reported, 
currently the interaction with HA appears to be the one most likely to directly activate 
intracellular signals required to stimulate processes relevant to angiogenesis (Savani et 
al., 2001). Indeed intracellular hyaluronan-binding molecules (hyaladherins) translocate 
to the nucleus, serving as substrates or activators for crucial signaling kinases or acting 
as vertebrate homologs of proteins involved in cell growth and differentiation, as well 
as in modulation of ECM and rearrangement of the cytoskeleton (Takahashi et al., 
2005). 
In particular, CD44 is a type 1 transmembrane glycoprotein that is expressed by most 
cell types, including ECs, and is considered the major receptor for HA. It’s expressed 
also on bone marrow-derived cells such as recruited leukocytes, tissue macrophages, 
and circulating EPCs that participate in angiogenesis (Cao et al., 2006). It is worthy of 
note that CD44 is highly expressed by human MSCs.  
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1.6.2 Butyric acid (BU) 
Butyric acid (sodium salt), a volatile short-chain fatty acid (fig. 1.13), is the most 
common and physiologic member of histone deacetylase (HDAC) inhibitors because it 
is formed in the colon by fermentation of dietary fibers. This small molecular weight 
molecule belongs to class I HDAC inhibitors, and exerts its action by altering chromatin 
structure and consequently increasing transcription factor accessibility to target cis-
acting regulatory sites. 
In detail, butyric acid inhibits the function of histone deacetylase enzymes, thereby 
favoring an acetylated state of histones in the cell. Acetylated histones have a lower 
affinity for DNA compared with non-acetylated histones, due to the neutralization of 
electrostatic charge interactions. In general, it is thought that transcription factors will 
be unable to access regions where histones are tightly associated with DNA (i.e. non-
acetylated, e.g. heterochromatin). Therefore, butyric acid is thought to enhance the 
transcriptional activity at promoters, which are typically silenced or down-regulated due 
to HDAC activity.  
 
 
 
    
 
Anyway, given the known function of histone acetylation in transcription, it seems 
logical to postulate that inhibition of HDACs alone is unlikely to lead to a generalized 
increase in the transcription of all known genes. In fact, acetylation works together with 
other post-translational modifications, and blocking deacetylation might have very 
different outcomes depending on the previous chromatin state. Up to 20% of all known 
genes are affected by HDAC inhibitors (Van Lint et al., 1996). Not all of these genes are 
necessarily up-regulated by treatment (the ratio of up-regulated to down-regulated genes 
is close to 1:1). 
1.6.3 Retinoic acid (RA) 
Retinoic acid (RA) is a natural occurring retinoid derivative of Vitamin A (retinol) 
that exerts a wide variety of profound effects on vertebrate development (fig. 1.14). 
Figure 1.13 - Butyric acid structure. 
1 - Introduction 
 
45 
 
Vitamin A is an essential nutrient, required for crucial biological functions in quantities 
that far exceed what can be metabolically generated. Thus, survival of mammalian and 
avian species is dependent upon acquisition of adequate dietary vitamin A, which must 
be enzymatically converted to active RA. The terminal step in RA synthesis is carried 
out by members of the class I aldehyde dehydrogenase (ALDH) family. Embryos 
lacking this enzyme are RA deficient and die in utero at E10.5.  
The RA signal is transduced through two families of ligand dependent transcriptional 
regulators, RA receptors (RARs) and retinoid X receptors (RXR), which bind as 
heterodimers to DNA motifs (RA response elements, RAREs), thus regulating the 
transcriptional activity of target genes controlling differentiation of a variety of cell 
types (Lai et al., 2003).  
 
                             
 
 
Lack of retinaldehyde dehydrogenase 2 (Raldh2) expression in the yolk sac is 
correlated with disrupted formation of extra-embryonic vessels in Raldh2
–/–
 mutants. 
However, Raldh2
–/–
 embryos also exhibit defects in heart looping morphogenesis, and 
severely hypoplastic atria and sinus venosus development. Vascular defects can be the 
indirect result of cardiac malformations. Anyway, histological examination revealed 
vascular malformations in RA-deficient yolk sacs and embryos prior to the onset of 
cardiac function and blood circulation. Cellular and molecular analyses indicated that 
RA was not required for EC differentiation, but was required for EC maturation and the 
control of cell cycle progression. Continuous RA supplementation of maternal diet 
restored cell cycle control and rescued the observed vascular defects in Raldh2
–/–
 
embryos and yolk sacs. 
Hence, RA plays a crucial role in mammalian vascular development, and is required 
throughout development to control EC growth and vascular remodeling.  
Therapeutic applications of RA and its derivatives against various malignancies have 
been increasing. Among other things, RA has been reported to be beneficial for 
Figure 1.14 - Structure of all-trans retinoic acid (atRA), 
one of the more active forms of RA. 
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atherosclerotic vascular disorders by inducing differentiation and inhibiting 
proliferation in vascular smooth muscle cells. Moreover, Uruno and colleagues have 
recently shown that RA increases nitric oxide production by eNOS phosphorylation 
through RAR-mediated PI3-kinase/Akt pathway activation in vascular ECs. Because 
NO is a potent vasodilator and signal modulator molecule and plays important roles in 
controlling vascular function, RA may be a candidate for novel therapeutic agents 
against vascular disorders with endothelial damage (Saito et al., 2007). 
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 EXPERIMENTAL DESIGN 
2 - AIM OF THE THESIS  
Mesenchymal stem cells have already made their mark in the young field of 
regenerative medicine. Easily derived from many adult tissues, their therapeutic worth 
has already been validated for a number of conditions. Unlike embryonic stem cells, 
neither their procurement nor their use is deemed controversial (Domìnguez-Bendala et 
al., 2012). Here we suggest the potential use of MSCs for the treatment of type 1 
diabetes mellitus, a devastating chronic disease in which the insulin-producing β-cells 
of the pancreas are the target of an autoimmune process.  
Islet transplantation is a form of cell therapy that has already proven effective at 
clinically restoring normoglycemia. The publication of the promising results of the 
Edmonton protocol in 2000 generated optimism for islet transplantation as a potential 
cure for T1DM. Unfortunately, follow-up data revealed that less than 10% of patients 
achieved long-term insulin independence. More recent data from other large trials show 
incremental improvement with 44% of islet transplant recipients maintaining insulin 
independence at three years of follow-up. Multiple underlying issues have been 
identified that contribute to islet graft failure, first of all the instant blood-mediated 
inflammatory reaction. Even hypoxia plays an important role in limiting the 
engraftment, survival and function of transplanted islets. MSCs were recently used in 
animal models of islet transplantation not only to reduce allograft rejection by immune 
modulation mechanisms (Berman et al., 2010), but also to promote islet 
revascularization (Ito et al., 2010).  
Beside bone marrow and human cord blood, adipose tissue represents a novel and 
high-throughput source for human MSCs (Zuk et al., 2002). Moreover, the capability of 
adipose-derived stem cells to improve islet graft revascularization was recently reported 
after hybrid transplantation in mice (Ohmura et al., 2010). Within this context, we have 
previously shown that hyaluronan esters of butyric and retinoic acids can significantly 
enhance the rescuing potential of human MSCs in both heart and kidney rat models of 
tissue damage (La Manna et al. 2010, Ventura et al. 2007), and that these beneficial 
effects were mediated by the transcriptional action of hyaluronan grafted moieties 
intracellularly released by the mixed ester. Based on these underpinnings, the aim of the 
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current thesis was to define a sort of chemical preconditioning able to increase the 
angiogenic potential of human ASCs in vitro. In particular we tried to find the best 
combination of naturally occurring molecules capable to enhance and optimize both 
vascular and perivascular cell commitment as well as paracrine secretion of angiogenic 
and anti-apoptotic factors. 
Then we investigated whether ex vivo preconditioning of human ASCs with a 
mixture of hyaluronic, butyric, and retinoic acids may result in optimization of graft 
revascularization and function after islet/stem cell intrahepatic cotransplantation in 
syngeneic diabetic rats.  
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3 - MATERIALS AND METHODS 
3.1 Adipose-derived stem cell isolation, culture and 
characterization  
3.1.1 Cell isolation 
According to the policy approved by the local ethical committee, all tissue samples 
were obtained after informed consent from healthy donors. Human subcutaneous 
adipose tissue samples were obtained from lipoaspiration/liposuction procedures from 
several regions of the body including hip, thigh and abdominal regions, and collected 
into a sterile container. After washing, lipoaspirates were digested with 0.2% 
collagenase A type I solution (Sigma-Aldrich), under gentle agitation for 45 min at 
37°C, and centrifuged at 650 xg for 10 min to separate the SVF from adipocytes. If 
necessary, the MSC fraction was treated with red blood cell lysis buffer for 5 min, and 
then centrifuged again. The supernatant was discarded and the cell pellet was 
resuspended and seeded in culture flasks in Dulbecco's Modified Eagle Medium 
(DMEM)-low glucose (Lonza) supplemented with 20% heat-inactivated fetal bovine 
serum (FBS), 1% penicillin-streptomycin, 2mM L-glutamine, and incubated at 37°C in 
a humidified atmosphere with 5% CO2. When the cultures were near confluence, the 
cells were detached by treatment with trypsin-EDTA solution (Sigma-Aldrich), 
characterized, subcultured and used at passage 3-5 (fig. 3.1). 
3.1.2 ASC expansion in culture  
The cultures at passage 0 were checked for several days under an optical microscope, 
the medium was changed twice a week, and when the flasks reached 90% confluence, 
the cells were collected and expanded. 
Cells were detached with trypsin-EDTA solution and replated at the desired density 
in culture medium supplemented with 20% (then 10%) FBS, subcultured for expansion 
and in vitro analysis (including characterization). Human ASCs maintain their 
characteristics at least until passage 8; for experiments cells from 3-6 passage were 
used. 
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3.2 Characterization 
3.2.1 Differentiation assays 
To evaluate the cell plasticity we tested the ability to differentiate into multiple tissue 
type lineages, by using commercial available kits. In particular cells derived from 
lipoaspirate should be able to undergo adipogenic, osteogenic, and chondrogenic 
differentiation (the classical 3 mesenchymal lineages).  
 
Figure 3.1 - Processing of lipoaspirate and isolation of adipose-derived stem cells (right 
image: hASCs in culture, 100x original magnification) (modified from Gimble et al., 2007).  
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3.2.1.1 Adipogenic differentiation 
ASCs were seeded at a density of 2 x 10
4
 cells/cm
2
 in a 24-well microplate, cultured 
until 100% confluence, and treated with DMEM-low glucose supplemented with 10% 
FBS, 0.1 µM dexamethasone, 0.5 mM isobutyl-methyl xanthine (IBMX), 100 µM 
indomethacin, 10 µg/ml insulin, 1% penicillin-streptomycin (Mesenchymal Stem Cell 
Adipogenesis Kit, Chemicon International). The induction medium was replaced every 
2-3 days, interchanging with cycles of adipogenesis maintenance medium containing 
DMEM-low glucose supplemented with 10% FBS, 10 µg/ml insulin, 1% penicillin-
streptomycin.  
Control cells were cultured in basal medium (DMEM/10% FBS) and finally assayed 
in the same manner. 
After 2-3 weeks of culture, induced cells, observed with optical microscope, should 
show storages of neutral lipids in cytoplasmic vacuoles; the cells were fixed with 10% 
formalin and stained with Oil Red-O that specifically highlights lipids in the mature 
adipocytes. 
3.2.1.2 Osteogenic differentiation 
ASCs were seeded at a density of 2 x 10
4
 cells/cm
2
 in a 24-well microplate, cultured 
until 100% confluence, and treated with DMEM-low glucose supplemented with 10% 
FBS, 10 mM glycerol-2-phosphate, 0.2 mM ascorbic acid 2-phosphate, 0.1 µM 
dexamethasone, 1% L-glutamine, 1% penicillin-streptomycin (Mesenchymal Stem Cell 
Osteogenesis Kit, Chemicon International). Control cells were cultured in basal medium 
(DMEM/10% FBS). 
The day before seeding the cells, the wells were coated with 0.5 ml of a 
vitronectin/collagen mixture prepared in PBS at a final concentration of 12 µg/ml for 
each ECM molecule. This solution was removed and washed just before plating. 
Cells were cultured for 3-4 weeks and the medium was changed every 2-3 days. To 
assess the occurred osteogenic differentiation, cells are fixed with 10% formaldehyde, 
and coloured with Alizarin Red Solution. Samples were observed under an inverted 
optical microscope (Nikon ECLIPSE TS100), equipped with a digital sight camera and 
the imaging software NIS-Elements (Nikon). 
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3.2.1.3 Chondrogenic differentiation 
Aliquots of 2.5 × 10
5
 ASCs were pelleted in polypropylene conical tubes, by 
centrifugation at 150 xg for 5 min. To induce chondrogenic differentiation, cell pellets 
were fed every 2-3 days by completely replacing the medium with 0.5 ml of freshly 
prepared complete chondrogenic medium: Chondrogenic Basal Medium supplemented 
with Supplements and Growth Factors (ITS + supplement, dexamethasone, ascorbate, 
sodium pyruvate, proline, penicillin-streptomycin, L-glutamine), and 10 ng/ml 
Transforming Growth Factor-β3 (all the reagents were purchased from Lonza). 
Chondrogenic pellets were harvested after 21 to 28 days in culture, formalin-fixed, 
then embedded in paraffin for histological analysis or to be freezed for the sectioning. 
The thin slices were mounted on slides, examined morphologically and immunostained 
for the research of GAG with Alcian blue or type II collagen. 
3.3 Preconditioning of hASCs 
The use of a cell preconditioning strategy has the aim to evaluate how natural 
molecules like HA, BU, and RA can affect the cellular pattern, and address a possible 
vascular/perivascular commitment.  
Human ASCs were seeded at 8 x 10
3
 cells/cm
2
 in DMEM/20% FBS, and after 24 hours 
the medium was changed to DMEM/10% FBS containing low molecular weight HA (2 
mg/ml), BU (5 mM), and RA (1 μM). Chemicals were purchased from Sigma-Aldrich, 
except for 16.9 kDa hyaluronic acid which comes from Lifecore Biomedicals. Control 
cells were cultured in DMEM/10% FBS. 
3.4 Gene expression  
Total RNA from control or preconditioned hASCs was extracted at 1-3-6 days 
using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions, and 
quantified using Nanodrop. One μg of RNA from each sample was reverse-transcribed 
into cDNA in a 20-μl reaction volume with SuperScriptTM III reverse transcriptase 
(Invitrogen). To assess gene expression, 2 μl of cDNA were used for real-time PCR 
performed with a Lightcycler system (Roche Applied Science) and with the SYBR 
Green I FastStart kit (Lightcycler® FastStart DNA MasterPLUS SYBR Green I), 
following the manufacturer’s instructions.  
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Primers for real-time PCR were designed by using Primer3 program 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi), checked by 
BLAST (http://www.ncbi.nlm.nih.gov/BLAST), and ordered from Sigma-Aldrich. 
Primer sequences are shown in table 3.1; each forward/reverse primer was used at a 
final concentration of 0.25 μM. Amplification program: denaturation at 95°C for 10 
min; 40 cycles of denaturation at 95°C for 8 s, annealing at 55-65°C (depending on the 
melting temperature of each couple of primers) for 8 s, extension at 72°C for 5 s. 
Fluorescence is measured at the end of every cycle. The melting curve program is 
performed starting at 55°C and ending at 95°C, with increments of 0.1°C/second and a 
continuous fluorescence measurement. The final step is cooling to 4°C. 
 
Table 3.1 - PCR primer sequences (5’-3’). 
 
Data were normalized using three housekeeping genes (beta-actin ACTB, 
glyceraldehyde 3-phosphate dehydrogenase GAPDH, hypoxanthine 
phosphoribosyltransferase 1 HPRT1) as an index of cDNA content after reverse 
transcription. Relative quantification of mRNA expression was calculated with the 
comparative Ct method using the “delta-delta method” for comparing relative 
expression results between treatments in real-time PCR (Pfaffl, 2001).  
3.5 Secretome analysis 
To investigate whether the mixture of HA, BU, and RA may affect the production of 
angiogenic and anti-apoptotic factors, we performed some enzyme immunoassays 
(Human HGF ELISA Kit and Human VEGF ELISA Kit, from Boster Biosciences Co., 
LTD). 
GENES Forward (5’-3’) Reverse (5’-3’) 
ACTB CACCATTGGCAATGAGCGGTTC AGGTCTTTGCGGATGTCCACGT  
GAPDH CAGCCTCAAGATCATCAGCA  TGTGGTCATGAGTCCTTCCA  
HPRT-1 CATTATGCTGAGGATTTGGAAAGG CTTGAGCACACAGAGGGCTACA 
VEGF AGAAGGAGGAGGGCAGAATC  ACACAGGATGGCTTGAAGATG  
KDR CTGCAAATTTGGAAACCTGTC  GAGCTCTGGCTACTGGTGATG 
HGF  ATTTGGCCATGAATTTGACCT  ACTCCAGGGCTGACATTTGAT 
ISL1 GAGGGTTTCTCCGGATTTGG TCCCATCCCTAACAAAGCATGT 
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Samples were prepared starting from cells, cultured in absence (control) or presence 
(preconditioned) of HA, BU, and RA in DMEM supplemented with a reduced 
concentration of FBS (2%) to limit the possible interference of factors normally 
contained in serum. 
At defined time points (1-2-3-6 days) cell media were collected, and centrifuged to 
remove particulates/debris. Cell supernatants were dispensed into ELISA plate wells, 
and assayed immediately according to the manufacturer’s instructions or aliquoted and 
stored at -20°C. 
Plates were read on an Opsys MR Microplate Reader (Dynex Technologies) at an 
optical density (O.D.) of 450 nm. For each well the relative O.D. was calculated 
according to the formula: (relative O.D.) = (O.D.450) - (O.D.450 of Zero well). The 
standard curve was plotted as the relative O.D.450 of each standard solution (Y) vs. the 
respective concentration of the standard solution (X). The unknown cytokine 
concentrations in the samples (pg/ml) were interpolated from the standard curve. For 
each sample, cell proteins were extracted by trichloroacetic acid (TCA) 
precipitation/NaOH lysis, and the total protein amount was quantified by Bradford 
assay, and used for normalization. Data are expressed as pg of secreted factor per μg of 
protein at the time of harvest. 
3.6 Flow cytometry analysis: hASC characterization and 
expression of perivascular/vascular markers  
For characterizing hASCs as mesenchymal stem cells, as well as assessing if 
treatment with HA, BU, and RA could change protein expression, we harvested cells by 
trypsinization, washed with phosphate buffered saline (PBS), and centrifuged at 650 xg 
for 5 min at room temperature. After removing the supernatant, the cell pellet was 
resuspended with a solution of 1% BSA (Bovine Serum Albumin) in PBS, and divided 
into aliquots (each of at least 1 x 10
5
 cells). One aliquot was used as negative to acquire 
cell parameters, the others were marked adding fluorescent specific anti-human 
antibodies (1 μg/106 cells) for 40 min at 4°C in the dark.  
In case of NG2, two different incubations were necessary: the first one with the 
primary antibody (mouse anti-human NG2, Millipore) and, after a washing step, the 
second one in presence of the secondary antibody (goat anti-mouse IgG Alexa Fluor 
555, Invitrogen). 
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Finally cells were washed with BSA/PBS and centrifuged. The pellet was 
resuspended with 300 µl of BSA/PBS, and cells analyzed on a flow cytometer 
(FACSAria, BD Biosciences) by collecting 10,000 events. Data were processed using 
the FACSDiva Software. 
To characterize ASCs we used a MSC specific panel of antibodies conjugated with 
different fluorophores including anti-CD90-R-PE and anti-CD105-FITC (Biolegend), 
anti-CD14-APC, anti-CD29-PE-Cy5, anti-CD34-FITC, anti-CD44-FITC, anti-CD45-
PerCP, anti-CD73-PE, anti-CD166-R-PE (BD Biosciences). Other investigated markers 
were CD146-Alexa647, PDGF-Rβ-PE, KDR-PerCP/Cy5.5 (Biolegend). 
Flow cytometry analysis was also exploited to assess the percentage of cells 
expressing alpha smooth muscle actin (α-SMA), an intracellular antigen requiring a 
different preparation protocol. After 10-min fixation with 0.25% formaldehyde on ice, 
followed by 15-min permeabilization with 1% Tween20, ASCs were incubated with an 
anti-human antibody directed against α-SMA (FITC-conjugated, AbCam) for 30 min at 
4°C in the dark.  
3.7 Immunofluorescent analysis  
Immunofluorescence allows the identification of cell or tissue antigens through the 
employment of specific antibodies conjugated with fluorescent dyes (fluorophores). The 
samples are observed with a fluorescence microscope that excites the fluorophore, 
detecting its signal and showing the potential presence and localization/distribution 
within the cell. By means of this technique, we researched the presence of some 
vascular protein, as well as the expression of endothelial markers (CD31 and von 
Willebrand Factor, vWF) in cells cultured up to 14 days in absence (control) or presence 
of HA, BU, and RA (preconditioned). After 14 days cells, which had been grown in 24-
well microplate on sterile glass coverslips, were fixed with ice cold methanol for 10 min 
on ice. Only for intracellular antigen detection, cells were also permeabilized with 0.2% 
Triton X-100 for 10 min at room temperature. Non-specific antibody binding sites were 
blocked by incubating the cells with 4% BSA/PBS for at least 30 min at room 
temperature (or overnight at 4°C). The blocking solution was then carefully removed 
and the cells were incubated for 45 min at 37°C with the primary antibodies (or 
conjugated antibodies). Following several washing in PBS/Tween 20 (0.25 %), the 
samples were incubated with the secondary antibody (where needed) for 45 min at 37°C 
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in the dark. After this incubation time, the cells were extensively washed, then the 
nuclei were counterstained with DAPI solution (0.1 μg/ml final concentration, 
Invitrogen). The samples were mounted with antifade reagent (ProLong® Gold, 
Invitrogen). Negative controls were done by omitting the primary antibodies. Samples 
were observed under a fluorescence microscope (Nikon), and images acquired and 
merged with a digital camera through the imaging software NIS-Elements. 
Used antibodies: 
 Mouse anti-human PECAM-1 (CD31) (1:50 dilution, Santa Cruz); 
 Monoclonal mouse anti-human von Willebrand Factor (vWF, 1:30 dilution, 
DakoCytomation); 
 Mouse anti-human chondroitin sulfate proteoglycan (NG2, 1:100 dilution, 
Millipore); 
 Goat anti-mouse IgG Alexa Fluor 555 (1:1000 dilution, Invitrogen); 
 Mouse monoclonal anti-alpha smooth muscle Actin (FITC) (-SMA, 1:100 dilution, 
AbCam). 
3.8 Vasculogenesis (in vitro study of angiogenic potential) 
ASCs express markers and functional properties of pericytes in vitro and, in 
combination with endothelial cells, are able to establish multilayer functional vessels in 
vivo (Traktuev et al., 2009). However, the factors that coordinate EC-ASC 
communications to promote migration of these cells toward one another, and their 
heterotypic assembly into vascular structures are not well defined. To understand the 
mechanisms of EC-ASC interaction, we drew inspiration from the in vitro model 
published by Merfeld-Clauss and colleagues, which consists in coculturing ECs with 
ASCs, without additional exogenous cytokines or extracellular matrix proteins. 
The culture medium we used was a 1:1 mixture of Endothelial Basal Medium EBM-
2/DMEM-low glucose containing 5% FBS. At first ASCs were seeded in a 24-well 
microplate on sterile glass cover slips with a density of 4 x 10
4
 cells/cm
2
; after 4 hours 
in the same wells HUVECs (Human Umbilical Vein Endothelial Cells) were seeded (1 
x 10
4
 cells/cm
2
). For negative control with the same procedure we plated Human 
Foreskin Fibroblasts (HFFs) in place of hASCs, and HUVECs after 4 hours. 
In the aftermath we observed the wells with an optical microscope, and fixed cells 
for fluorescence immunostaining between 2-6 days from coculture beginning. 
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Following the protocol described in the previous paragraph, we stained cocultures with 
endothelial markers (CD31 and vWF), to analyze how HUVECs reorganized 
themselves to eventually form cord structures, and with α-SMA antibody to indagate 
how its expression in ASCs eventually changed. 
3.9 In vivo study 
3.9.1 Experimental animals 
Male Lewis rats were purchased from Charles River Laboratories, Inc. Rats weighing 
approximately 200 g were used as recipients, and those weighing 300-350 g were used 
as donors. The use of animals and the animal procedures of this study were approved by 
the Bioethics Committee of the University of Bologna.  
3.9.2 Isolation and culture of rat pancreatic islets 
Rats were anesthetized with Isoflurane (Abbott Laboratories), and subsequently 
sacrificed by neck dislocation. Islet isolation and purification were performed according 
to a modified procedure described earlier (Gotoh et al., 1985). Briefly, after cannulation 
of the common bile duct, 10 ml of enzyme solution of collagenase NB8 (SERVA 
Electrophoresis), at a concentration of 1.3 mg/ml in Hank’s Balanced Salt Solution 
(HBSS), were injected by retrograde perfusion of the pancreas. After organ 
procurement, enzymatic digestion took place for 12-15 min at 37°C in a water bath with 
two intermitted 1-min periods of vigorous shaking. Following a wash step with 10% 
FBS/HBSS and filtration through cheesecloth, islets were obtained by centrifugation in 
a discontinuous density gradient of Histopaque 1077 (Sigma-Aldrich) and HBSS, with 
subsequent hand-picking and microscope examination. The total number of islets in 
each diameter class was counted using an optical graticule. The number was then 
converted to the standard number of islet equivalents. Islet viability was assessed using 
fluorescent staining with acridine orange and propidium iodide (Sigma-Aldrich). Islets 
with viability >90% were used for transplantation purposes.  
Immediately after counting, isolated rat islets (fig. 3.2-A) were incubated with 
hASCs (fig. 3.2-B) that had been previously preconditioned for 5 days (as already 
described above). To facilitate the adhesion of hASCs to the islet surface, we used the 
procedure described by Johansson and colleagues in 2008. In brief, the total volume of 
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isolated islets was mixed with control or preconditioned hASCs at a cell/islet ratio of 
5,000/100 in islet medium RPMI-1640 (Lonza), supplemented with 10% FBS, 2 mM L-
glutamine, 1% antibiotic-antimycotic solution. The cell suspensions were incubated at 
37°C for 2 hours in culture tubes, and mixed gently twice per hour. Thereafter, the 
mixture of islets and hASCs was seeded in ultra-low attachment plates (Corning), and 
cultured for up to 3 days in a humidified incubator at 37°C, 5% CO2 (fig. 3.2-C). 
 
 
 
 
 
 
To detect the capability of hASCs to adhere to the islet surface, in a pilot test we 
cultured islets with hASCs transfected with green fluorescent protein (GFP). At the end 
of a 3-day coculture period, the eventual formation of composite hASCs-islets was 
evaluated by immunofluorescence microscopy. 
For transplant purpose, at the end of the coculture period, islets and hASCs were 
hand-picked, washed 3 times with 10 ml of HBSS containing 2% Lewis rat serum, 
suspended in transplant medium (HBSS/10% rat serum), and kept on ice into a sterile 
Eppendorf tube until the time of transplantation.  
Figure 3.2 - Islets cocultured with hASCs. Isolated rat islets (A, magnification 40x), and 
hASCs (B, magnification 100x) were cocultured up to 3 days (C). Scale bar = 50 μm. 
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3.9.3 Cotransplantation of islets and hASCs, and monitoring of 
islet graft function  
Diabetes was induced in rats by a single 70 mg/kg intraperitoneal injection of 
streptozotocin (Sigma-Aldrich). Only rats with blood glucose levels of more than 400 
mg/dl for 3 consecutive days were used as recipients of islet grafts. The animals were 
anesthetized with xylazine-tiletamine-zolazepam (Zoletil®, Virbac), and placed on a 
deltaphase heating pad (2Biol). A suboptimal volume of 500 cultured islets (2,500 
islet/Kg), that in our experience allowed the reduction of blood glucose levels of 
transplanted rats without achieving reversal of diabetes, and the cocultured control or 
preconditioned hASCs were transplanted in diabetic rats weighing approximately 200 g 
(n=7 per group, control or preconditioned group, respectively). With the aim to favor 
graft detection after intraportal injection and to permit a comparative analysis between 
the two study groups, we transplanted islets only in the caudate lobe of the rat liver, as 
already described (Kugelmeier et al., 2008). Briefly, the cavity was accessed by midline 
incision. The portal branches to the left, middle and right liver lobes were temporarily 
closed with microvascular clamps, after which islets of both study groups were slowly 
injected into the portal vein by a 26-gauge needle, in a volume of 300 μl of transplant 
medium, directing the islets to the caudate liver lobe (fig. 3.3). The clamps were 
released and the injection needle was removed. Bleeding was stopped with a cotton 
swap by gentle compression at the site of injection. After closing the abdomen with 
sutures, the recipient was allowed to recover.  
 
   
 
 
Figure 3.3 - Pancreatic islets were injected in the portal vein and selectively directed in the 
caudate lobe of the rat liver. 
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On the 15
th
 post-transplantation day, intraperitoneal glucose tolerance test (IPGTT) 
was performed. After overnight fasting, rats were intraperitoneally injected with normal 
saline containing 2 g glucose/kg of body weight. Glucose disposal was analyzed by 
measuring blood glucose levels at 30, 60, 90, and 120 min after injection by tail 
snipping (fig. 3.4). 
 
 
 
 
3.9.4 Morphological and immunohistochemical examination  
At the end of a 3-day coculture period, islet morphology was evaluated by direct 
microscopic observation, then prepared for histological examination (ex vivo analysis). 
Islets were fixed in Bouin solution, embedded in 2% agarose in PBS, and then allowed 
to polymerize on ice. The enrobed islets were processed for paraffin embedding and 4-
μm sections were cut on a microtome (Leica RM2125RT). Sections were deparaffinized 
in xylene, rehydrated through decreasing concentrations of ethanol, and stained with 
hematoxylin and eosin (H&E). Deparaffinized sections were placed in TRIS/EDTA 
Buffer (pH 9.0), and heated for 1 min in a pressure cooker (110°C) for antigen retrieval. 
Subsequently, retrieved sections were blocked with 2% normal goat serum (NGS) in 1% 
BSA in PBS for 30 min at room temperature. The slides were then incubated with the 
anti-human mitochondria monoclonal antibody, clone 113-1 (1:50, Millipore) for 60 
min at room temperature to evaluate the adhesion of the human MSCs to the islets. The 
14
7
7
Tx islets + hASCs
Tx islets + prec. hASCs
Figure 3.4 - Experimental design for islet/stem cell intrahepatic cotransplantation in 
syngeneic diabetic rats (Tx: transplant, STZ: streptozotocin). 
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islet sections were then stained for immunofluorescence by the mouse anti-insulin 
monoclonal antibody clone K36AC10 (1:500, Sigma-Aldrich) used at 4°C for 
overnight, followed by the secondary antibodies anti-mouse IgG (Fc specific) FITC-
conjugated (1:250, Sigma-Aldrich) or Alexa Fluor® 555 (1:1000, Invitrogen) in 1% 
BSA in PBS for 1 hour at 37°C to evaluate β-cell viability. To detect intraislet 
endothelial cells, lectin Bandeiraea simplicifolia (BS-1) TRITC-conjugated (1:100, 
Sigma-Aldrich) was employed in 1% BSA in PBS for 45 min at 37°C, after a second 
blocking with normal mouse serum (NMS) for 30 min at room temperature. 
To evaluate islet graft morphology and in particular their revascularization process in 
vivo, immediately after sacrifice the caudate liver lobes were harvested from the 
transplanted rats, fixed in formalin solution for 24 hours, embedded in paraffin, and cut 
into 4-µm sections. Paraffin sections were stained for insulin and lectin BS-1 using the 
same products reported above. To evaluate the level of the islet graft revascularization, 
the number of insulin-positive cells and lectin BS-1-positive capillary segments were 
counted in 7 pictures randomly selected for both study groups, and the obtained 
capillary/β-cell ratios were compared.  
Furthermore, to evaluate the presence of hASCs after transplantation, sections were 
stained with the anti-human mitochondria monoclonal antibody plus the secondary goat 
anti-mouse Alexa Fluor® 488 (1:250, Invitrogen) in 1% BSA in PBS for 1 hour at 
37°C. Samples were coverslipped with ProLong antifade reagent with DAPI (Molecular 
Probes). 
Slides were studied with a Leica DMI4000 B inverted fluorescence microscope and 
the image acquisition LAS AF software (Leica Microsystems).  
3.10 Statistical analysis 
Data are presented as mean ± SEM (standard error of the mean), or mean ± SD 
(standard deviation). Statistical comparison of two groups was carried out by two-sided 
unpaired Student’s t test and log-rank test. Comparison of more than two groups was 
performed by one-way ANOVA, followed by Bonferroni post hoc test (GraphPad Prism 
ver.5). A p value less than 0.05 was assumed as the limit of significance. * denotes 
significance level of p<0.05, ** p<0.01, and *** p<0.001.  
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4 - RESULTS 
4.1 Immunophenotypic characterization of hASCs 
Human mesenchymal stem cells isolated from adipose tissue (hASCs) grew adherent 
to plastic flasks, with a fibroblast-like morphology (fig. 4.1).  
 
 
 
 
4.1.1 Cytofluorometric analysis of mesenchymal markers 
Immunophenotypic characterization was assessed by flow cytometry analysis, 
measuring the fluorescence expression of the following conjugated monoclonal 
antibody: CD14-APC, CD29-PECy5, CD34-FITC, CD44-FITC, CD45-PerCP, CD73-
PE, CD90-R-PE, CD105-FITC, CD166-R-PE.  
ASCs were positively stained (>90%) with an epitope of endoglin (CD105 or SH2), 
the TGF-β receptor III present on endothelial cells, erythroblasts, monocytes, and 
connective tissue stromal cells. They were positive for CD73 (SH3/SH4), a molecule 
involved in B-cell activation, and for CD29, the β-subunit of an integrin family 
behaving as the major receptor for ECM molecules. Cells also expressed CD166, an 
hMSC marker not found in hematopoietic precursors, and were uniformly positive for 
Figure 4.1 - Human ASCs in culture at passage 0, 5 days after 
the first seeding (original magnification, 100x). 
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the CD44 hyaluronate receptor (fig. 4.2). Conversely, antigen profiles were negative for 
the hematopoietic markers CD14 and CD34, and the leukocyte common antigen CD45. 
This analysis of surface antigen expression indicates that hASCs can be regarded as 
alternative sources for hMSC-like elements.    
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Figure 4.2 - Flow cytometry histograms show the immunophenotypic profile of 
hASCs: unstained hASCs (negative control, grey); stained hASCs (violet). 
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4.1.2 Differentiation tests 
Differentiation assays in vitro further confirmed that the cell population isolated from 
adipose tissue was mesenchymal. Classical differentiations toward an adipogenic, 
osteogenic or chondrogenic fate were induced by using lineage-specific induction 
media. As showed in figure 4.3 (left panels), Oil Red-O staining, which highlights the 
accumulation of lipid vacuoles within the cytoplasm, confirmed the ability of hASCs to 
become mature adipocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 -  Induction of classical mesenchymal differentiations in hASCs: 
adipogenic differentiation (left panels), and osteogenic differentiation (right panels). 
From top to bottom: positive samples (original magnification 100x and 200x 
respectively), control negative (original magnification 40x). 
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Human ASCs could also differentiate into cells functionally able to mineralize the 
extracellular matrix with calcium salts, as revealed by histochemical staining with 
Alizarin Red (fig. 4.3, right panels).  
At the end of the chondrogenic differentiation assay, cells gave origin to a pellet 
which stained positive for Alcian blue (which colours sulphated glycosaminoglycans, 
GAGs), indicating that a chondrogenic matrix has formed (fig. 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 Gene expression analysis  
Real-time PCR provided evidence that stem cell preconditioning increased the 
transcription of genes that have been shown to play a crucial role in the orchestration of 
angiogenic signals, including VEGF, KDR, encoding a major VEGF receptor, HGF and 
ISL1 (Islet-1).  
Data were normalized using three housekeeping genes (ACTB, GAPDH, HPRT1) as 
an index of cDNA content after reverse transcription. Relative quantification of mRNA 
expression was calculated with the comparative Ct method using the “delta-delta 
method” for comparing relative expression results between treatments in real-time PCR 
(Pfaffl, 2001).  
In detail, VEGF expression (fig. 4.5-A) peaked at 24 hours after treatment with 
BU+RA, then it decreased in spite of maintaining its level higher than control cells. The 
transcriptional response to HA+BU+RA was even more remarkable compared to 
BU+RA, reaching a nearly 3-fold increase at 1 day (compared to 2.1-fold of BU+RA, at 
the same time point). Down-regulation of VEGF gene (concomitant to the increased 
VEGF secretion showed in figure 4.6-A) suggested that an autocrine regulation was 
likely to occur.  
Figure 4.4 -  Induction of chondrogenesis in hASCs: from left to right, control negative, 
positive samples stained respectively with Alcian blue pH 1 and pH 2.5. 
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Figure 4.5 - Enhanced angiogenic gene expression in treated hASCs. The abundance of 
each mRNA in control cells was defined as 1, and the amounts of VEGF (A), KDR (B), or 
HGF (C) mRNA from treated cells are plotted relative to that value. Values are mean ± 
SEM (n=3). * p<0.05, ** p<0.01, *** p<0.001 vs. control; § p<0.05, §§ p<0.01, §§§ 
p<0.001 vs. BU+RA. 
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Treatment with HA+BU+RA dramatically enhanced KDR expression (fig. 4.5-B) 
starting as early as 1 day and peaking at 6 days, reaching more than a 40-fold increase, 
as compared with control cells, while BU+RA peaks at 1 day decreasing with time. 
Concerning HGF (fig. 4.5-C), chemical preconditioning with BU+RA increased its 
expression significantly at all the time points, peaking at 3 days. HA+BU+RA treatment 
obtained the same trend but at a lower extent compared with BU+RA (fold increase: 
2.79 vs. 4.28 at 1 day, 4.94 vs. 6.94 at 3 days, 1.99 vs. 4.54 at 6 days). 
In further experiments, when the combination HA+BU+RA had already been chosen 
for the preconditioning, we analyzed the expression of ISL1 gene. During embryonic 
development, ISL1 has been identified as a marker for cardiovascular progenitor cells 
that form the three major cell types in the heart (cardiac, smooth muscle, and 
endothelial cells). In addition, it is a marker for endocrine progenitor cells in the 
pancreas, playing a critical role in the development of mature islet β-cells. ISL1, 
together with PDX-1 and Sonic hedgehog (Shh), affects the early events of pancreas 
development (Sordi et al., 2008). 
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The treatment with HA+BU+RA increased the ISL1 gene expression significantly at 
3 days (2.52-fold increase, fig. 4.6), showing a trend similar to HGF gene. Worthy to 
note, ISL1 is a master transcription factor which may influence pro-angiogenic and pro-
vasculogenic programs in adult MSCs. Barzelay et al. showed the potential of ISL1 in 
Figure 4.6 - Enhanced ISL1 gene expression in treated hASCs. The 
amounts of mRNA from treated cells are plotted relative to 
abundance of mRNA in control cells. Values are mean ± SEM (n=3). 
*** p<0.001.  
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promoting postnatal angiogenesis and vasculogenesis by triggering the intrinsic pro-
angiogenic functional properties of these cells, as well as by endowing paracrine 
amplification on angiogenesis.  
4.3 Cytokine secretion 
Cytokine secretion analysis was performed over a 6-day period in basal medium with 
2% FBS. ELISA revealed that control hASCs secreted consistent amounts of VEGF 
throughout the investigated time course. Noteworthy, culturing of hASCs in the 
presence of the preconditioning mixture resulted in a time-dependent increase in VEGF 
secretion, starting as early as 24 hours, and peaking after 6-day exposure (fig. 4.7-A).  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 - Enhanced cytokine secretion in treated hASCs. Time-course analysis of VEGF 
(A), and HGF (B) released by hASCs cultured for up to 6 days in the absence (black bar) or 
presence of natural molecules (light blue bars). Values are mean ± SEM (n=3). * p<0.05, ** 
p<0.01, *** p<0.001 vs. control; § p<0.05, §§§ p<0.001 vs. BU+RA. 
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The increase was more remarkable in case of HA+BU+RA treatment, which resulted 
not only significantly different (higher) than control at all the time points, but also 
higher than BU+RA treated-cells (significantly from 2 to 6 days, p<0.05).  
Concerning HGF, only the combination HA+BU+RA was able to significantly 
increase its secretion from hASCs. This treatment caused a peak of HGF release at 24 
hours (the first investigated time point), followed by a decrease, probably due to a 
saturation effect or negative feedback (fig. 4.7-B).  
4.4 Flow cytometry analysis of perivascular and vascular 
markers 
Based on previously obtained data, we chose the combination of molecules that in 
our opinion could be able to best force a vascular/perivascular fate: HA+BU+RA. Flow 
cytometry analysis, performed after 14 days of treatment (only one induction), showed 
that combined exposure to 2 mg/ml HA, 5 mM BU and 1µM RA remarkably augmented 
the percentage of cells expressing perivascular markers, like CD146 and NG2 (p<0.01 
and p<0.05 respectively), compared to control (fig. 4.8).  
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Figure 4.8 - Histogram of flow cytometry analysis for vascular/perivascular markers 
in hASCs 14 days after treatment. Below a table with percentage values. Data are 
mean ± SD (n=3).  
*** 
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Expression of PDGF-Rβ, that can be involved in proliferation of undifferentiated 
cells, is dramatically reduced in preconditioned cells, suggesting a possible cellular 
commitment. Alpha-SMA, KDR, CD34, and CD105 didn’t change significantly.  
4.5 Immunofluorescence 
The protein expression profile investigated by flow cytometry was confirmed by 
means of immunofluorescent analysis (fig. 4.9), that highlighted the presence of the 
pericytic protein NG2 (panel A) as well as the marker for endothelial specification vWF 
(panel B), not detectable in untreated cells. The amount of α-SMA-positive cells was 
not different in the two groups, but the fluorescence intensity was higher with 
HA+BU+RA preconditioning (panels C,D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6 Vasculogenesis 
We performed cocultures of ASCs and HUVECs to estimate in vitro the relevance of 
the contact between the two different cells types and to assess whether cell-to-cell 
interaction may induce a differentiation of ASCs toward a vasculogenic lineage. We 
Figure 4.9 -  Immunofluorescent staining of hASCs after 14-day culturing in presence 
of HA+BU+RA. NG2-positive (red, A) and vWF-positive cells (red, B); original 
magnification, 1000x. Alpha-SMA-positive cells cultured in absence (green, C) or 
presence (green, D) of the three molecules. Nuclei are counterstained with DAPI (blue).  
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analyzed whether the treatment with HA+BU+RA can increase or induce this kind of 
differentiation, forcing vascular network formation, by immunofluorescence analysis. 
Endothelial cells (all vWF-positive), seeded over ASC monolayer, were able to 
organize into vascular network in both cases (control or preconditioned cells, fig. 4.10), 
but not when seeded over HFF monolayer (data not shown). 
Anyway in the preconditioned samples costained with α-SMA, we observed an 
increased α-SMA expression in ASCs (recognizable also for the larger nuclei) and its 
organization into fibers, quite selectively in those ASCs that were in direct contact or in 
proximity with HUVECs. We can hypothesize that preconditioned ASCs could be more 
inclined to receive signals from HUVECs and differentiate toward a mural/perivascular 
cell type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 - Immunofluorescent staining of HUVECs cocultured for 6 days over a 
monolayer of ASCs, previously cultured for 5 days in absence (A) or presence of 
HA+BU+RA (B,C). Merged images: HUVECs are stained with anti-vWF antibody (red), 
ASCs (larger nuclei) are stained with anti -SMA (green); nuclei are counterstained with 
DAPI (blue). Original magnification, 400x. 
A 
B 
C 
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4.7 Formation of composite hASCs-islets 
Stem cell adhesion to the surface of cocultured islets was clearly detectable at 
microscopic examination using GFP-expressing hASCs. Approximately 50% of the 
islets presented hASCs on their surface at the end of the coculture period (fig. 4.11-A). 
The half part of the islets, however, appeared without hASCs coating their surface (fig. 
4.11-B).  
 
 
 
 
The formation of composite hASCs-islets was confirmed by immunohistochemistry 
using the anti-human mitochondria monoclonal antibody (fig. 4.12). No difference in 
the formation frequency of composite hASCs-islets was evidenced between the two 
study groups. Concerning the low number of hASCs linked to the islets, we have to 
consider that the formation of composite hASCs-islets is an accessory, although 
Figure 4.11 - Formation of composite hASCs-islets. The half part of islets 
remained uncovered (A), while approximately 50% of islets appeared covered by 
GFP-expressing hASCs (B), without difference between the two study groups.  
A 
B 
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favourable event, that is not mandatory to determine the revascularization of the 
transplanted islets. 
 
    
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.8 High presence of intraislet endothelial cells after coculture 
with preconditioned hASCs 
The majority of islets from both study groups, except for the occasional presence of 
central necrosis in the core region of the larger ones, showed an intact morphology at 
immunohistochemical examination at the end of the 3-day coculture period. 
Interestingly, by means of immunofluorescent analysis we were able to show that islets 
cultured with preconditioned hASCs revealed a higher presence of intraislet endothelial 
cells, as compared to islets from control group (fig. 4.13-A,B). Most part of the islets 
are marked green by antibodies anti-insulin, which specifically stain viable insulin-
producing β-cells (nuclei are blue). Red spots identify endothelial cells inside the islet.  
 
 
Figure 4.12 - Immunohistochemical analysis of composite hASCs-islets: detection of 
anti-human mitochondria-positive cells (arrows) in cultured rat pancreatic islets. Scale 
bar: 100 μm.  
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4.9 Cotransplantation of preconditioned hASCs enhances islet 
graft function 
With the aim of evaluating differences between the two study groups, for 
transplantation we used a marginal islet mass which was sufficient to improve glycemic 
control, but not to obtain a complete reversion of diabetes. Diabetic rats transplanted 
with 500 syngeneic islets of preconditioned group demonstrated enhanced glycemic 
control, compared with rats of control group. In particular, significant differences 
(p<0.05, p<0.01, p<0.001) in non-fasting glucose levels were registered between the 
rats of the two study groups at all the time points one week after transplantation (fig. 
4.14-A). The percentage of recipient rats with achievement of improved blood glucose 
control (non-fasting blood glucose <300 mg/dl for at least 3 consecutive days) is 
reported in fig. 4.14-B. Approximately 500 islets were sufficient to achieve a 
remarkable improvement in blood glucose control in 6 of 7 (85.7%) rats of 
preconditioned group, compared with 3 of 7 (42.8%) rats of control group (p<0.05 by 
log-rank test). Moreover, two of the recipients of preconditioned group (28.5%) became 
normoglycemic (non-fasting glucose <200mg/dl), while none of the rats of the control 
group achieved normal glucose levels. The IPGTT performed in overnight fasting rats 
15 days after transplantation detected significantly lower levels of blood glucose at 60 
Figure 4.13 - Immunofluorescent staining of 3-day cultured islets in presence of 
hASCs (A) or preconditioned hASCs (B). β-cells are stained with antibody anti-
insulin (green), intraislet ECs are stained with lectin BS-1 (red), and nuclei with 
DAPI (blue). Scale bar: 50 μm.  
A B 
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and 90 min (p<0.01) in the rats transplanted with islets of the preconditioned group (fig. 
4.14-C), confirming that preconditioning improved islet functionality. These results 
became more important considering some experiments previously performed in a group 
of rats using islet alone cultured for 3 days before transplant (data not shown). Here we 
observed a lower graft function compared to rats transplanted with an equal volume of 
islets cocultured with stem cells. 
 
 
 
 
Figure 4.14 - Improved islet graft function after cotransplantation with preconditioned hASCs. 
Daily measures of non-fasting glucose levels in diabetic rats after transplant (A). Percentage of 
recipient rats with improved glycemic control in the two study groups (B). IPGTT performed 
on the 15
th
 post-transplantation day in overnight fasting rats (C). * p<0.05, ** p<0.01, *** 
p<0.001 vs. control group at respective time points. 
A 
B 
C 
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4.10 Cotransplantation of preconditioned hASCs increases the 
revascularization process of transplanted islets 
Islet transplantation only in the caudate liver lobe of the recipient rats allowed the 
detection of a high number of islet grafts at the histological examination, and 
consequently permitted an accurate comparative immunohistochemical analysis of the 
graft vascularization between the two study groups (fig. 4.15). Two weeks after 
transplant, islets of preconditioned group showed intact β-cells detected by antibodies 
anti-insulin (fig. 4.15-A), and a dense capillary network stained with BS-1 (fig. 4.15-B). 
Graft revascularization appeared preferable in islets of preconditioned group (fig. 4.15-
C) compared to control group (fig. 4.15-D).  
 
  
 
 
 
 
As shown in fig. 4.16, the capillary number per β-cell in the islet graft of 
preconditioned group was sensibly superior to that of control group (n=7 sections 
examined per group) (0.117±0.02 vs. 0.062±0.02 capillary fragments per β-cell, 
p<0.01). The presence of anti-human mitochondria-positive cells, located in proximity 
Figure 4.15 - Enhanced islet graft revascularization by preconditioned hASCs 
cotransplantation two weeks after transplant. Islets of preconditioned group stained with 
antibody anti-insulin (A, green), and anti-lectin BS-1 (B, red). Merged photograph of A 
and B (C). Merged photograph of control group islet (D). Scale bar: 100 μm.  
A 
B 
C 
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of the engrafted β-cells, indicated the viability of hASCs for up to two weeks after 
transplantation (fig. 4.17).  
 
 
 
 
 
 
Thus, as reported by other authors in literature, hASCs are able to protect β-cell 
viability during pre-transplant coculture, preserving at least partially islet function and 
improving graft revascularization process after transplantation in an animal model. 
Together these in vivo results clearly show that our preconditioning strategy with 
natural molecules fulfilled to strengthen the aforementioned ASC ability. 
 
 
 
 
 
 
 
Figure 4.16 - Analysing 7 islet graft pictures for group, a higher 
capillary segments/β-cell ratio was detected in preconditioned 
vs. control group (** p<0.01).  
Figure 4.17 – Anti-human mitochondria-positive cells (green, 
arrows) revealed hASCs surrounding engrafted β-cells stained for 
insulin (red); scale bar: 25 μm.  
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5 - DISCUSSION 
The employment of MSCs to improve the efficacy of pancreatic islet transplantation 
represents a new promising research approach (Berman et al., 2010; Ito et al., 2010; 
Johansson et al., 2008; Park et al., 2010). Recently the ability of ASCs to enhance 
pancreatic islet engraftment and functionality by inhibition of inflammatory host 
response and improvement of graft revascularization was demonstrated in an animal 
model of diabetes (Ohmura et al., 2010). An important element involved in the 
maintenance of a good function of the graft is the secretion of anti-apoptotic and 
vasculogenic factors by MSCs (Zuk et al., 2002), that exert a protective effect on islet 
cells during the culture period, and increase the revascularization of transplanted islets 
(Brissova et al., 2006; Ito et al., 2010; Park et al., 2010). One of the most important 
cytokines produced by both mesenchymal stem cells and endothelial cells is VEGF, 
which has an anti-apoptotic effect and exerts a fundamental role in vessel development. 
During the procedure of islet isolation and culture, not only a significant portion of β-
cell mass but even intraislet endothelial cells, which are essential for the process of 
revascularization after transplant, get lost (Brissova et al., 2004; Nyqvist et al., 2005). 
Therefore, the reduced production of VEGF, caused by necrosis of endocrine cells, 
impairs the already poor process of post-transplant revascularization (Kampf et al., 
2006; Lau et al., 2009). 
In this study, we showed that the regenerative action exerted by hASCs could be 
increased by preconditioning these cells with a mixture of natural molecules as 
hyaluronic, butyric, and retinoic acids. Specifically, the intrahepatic transplantation of a 
subtherapeutic volume of islets cultured for 3 days in the presence of preconditioned 
hASCs showed an enhanced revascularization and function, compared to islets cultured 
with control cells. The beneficial effects of this new strategy may result from the ability 
of the preconditioning mixture to increase the gene and protein expression of VEGF, as 
well as the transcription of KDR, HGF, and ISL1 which have been shown to be 
involved in autocrine/paracrine circuitries of angiogenic signaling amplification 
(Ancelin et al., 2004; Millauer et al., 1993; Barzelay et al., 2010).  
The higher production of vasculogenic and anti-apoptotic cytokines by 
preconditioned cells, together with the increased expression of perivascular markers 
(CD146 and NG2), could also explain the higher presence of intraislet endothelial cells 
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in islets evaluated after a 3-day coculture with preconditioned hASCs, and the reduction 
of necrosis, that is only occasionally observed in the core region of larger islets.  
The in vivo studies indicate that the favorable pro-survival effect on intraislet 
endothelial cells, provided in vitro by stem cell preconditioning, leads to an improved 
vascular network after islet/preconditioned hASC cotransplantation in syngeneic 
diabetic rats, and that the animals subjected to this protocol could benefit from a 
remarkably enhanced glycemic control. This finding indicates that the currently 
described procedure not only preserves structural features of the islets and their inherent 
vascular network, but can also impact on the molecular plight that controls the 
attainment of a proper islet function. 
The use of adipose tissue as an alternative stem cell source is one of the most 
intriguing fields of recent interest. Fat can be used in autologous fashion, and exhibits 
ideal characteristics, being readily available, inexpensive, and host compatible. It is also 
abundant, can be repeatedly harvested with a minimally invasive procedure, and 
cryopreserved for banking and subsequent use in one of the several therapeutic 
applications that may be envisioned from hMSCs. Moreover, hASCs have already been 
used in clinical settings in the treatment of several pathologies (García-Olmo et al., 
2005; Rigotti et al., 2007; Valina et al., 2007), and their efficacy and safety allow their 
clinical use in the field of islet transplantation. 
It has been recently shown that lipoaspirates can also be processed with mild 
mechanical forces in the absence of any enzymatic digestion or growth factor additives, 
leading to a significant simplification and cost decrease in fat processing (Tremolada et 
al., 2010). Our preconditioning strategy may also be applied in principle to hASCs 
isolated from these non-enzymatic fat products, and studies are on the way to assess 
such a perspective.  
Although the rescuing ability of MSCs has been a driving force behind initial studies 
examining their therapeutic effectiveness, their immunomodulatory properties are 
equally exciting in terms of exploring their potential implications in various disease 
models, including autoimmune diseases, as type 1 diabetes (Anzalone et al., 2011). An 
important immunological feature of MSCs is the inhibition of T-cell proliferation and 
dendritic cell differentiation, due to their low expression of costimulatory molecules and 
the absence of class II HLA. In addition MSCs are able to synthesize trophic mediators 
involved in immunomodulation, and to induce T-cell anergy and regulatory T-cells 
(Zhou et al., 2011). One of the great expectations linked to the use of MSCs may 
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therefore reside in their ability to successfully engraft, evading an immune response and 
inducing peripheral host tolerance, allowing hMSC xenotransplantation (La Manna et 
al., 2011; Rossignol et al., 2009; Ventura et al., 2007; Zhou et al., 2011). 
The results from our study show that preconditioning with natural molecules 
increases the protective effect of hMSCs on cultured islets, improving their post-
transplant functionality and efficiency. These results may pave the way to an 
optimization in the employment of hASCs for islet transplantation, and may also lead to 
a consistent reduction in the total volume of islets necessary for the transplant.  
Nowadays several centers have adopted the strategy to perform two or more islet 
infusions in the same recipient using different pancreas donors, in order to extend the 
period of insulin independence after transplant. However, this strategy could increase 
not only the costs related to the procedure, but also the risk of sensitization of the 
patients. A period of islet culture, optimized with the employment of preconditioned 
hASCs, may provide several advantages in the clinical setting of islet transplantation, 
optimizing a number of critical features in this biomedical area of enquiry, including the 
quality of islet preparations, the availability of additional time for the selection and 
treatment of the recipient with suitable pre-transplant strategies (Shapiro et al., 2011), 
and the possibility to ship processed islets to remote transplant centers.  
The results of the Edmonton study showed that the outcome of the islet 
transplantation is strictly dependent on the experience of the isolation center (Shapiro et 
al., 2006): the strategy of creating regional centers isolating cells and sending them to 
other transplant centers has been successful so far (Goss et al., 2004; Kempf et al., 
2005). In particular, this type of collaboration allowed a decrease in the total procedure 
costs and an increase in the experience of the isolation center with a positive rebound on 
the percentage of successful isolations, and consequently on the number of the 
transplants performed. In this type of collaboration, the use of cultured islets is 
frequently required and a pre-transplant islet culture within 72 hours is considered as 
safe by most transplant centers. However, a short culture period could also be 
detrimental in the post-transplantation islet function, further reducing the already poor 
process of graft revascularization (Olsson et al., 2005). 
In order to move this field forward, human data will be necessary to provide 
confirmation of preclinical studies and provide further characterization of the 
therapeutic benefits offered by stem cells.  
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Concerning the possibility to apply preconditioning strategies in cell therapies to 
treat other diseases, studies are in progress to evaluate the effects of the injection of 
preconditioned hASCs as well as Lipogems in a rat model of hind limb ischemia, with 
special interest toward revascularization and perfusion recovery. Should future studies 
confirm our promising results, then the employment of hASCs preconditioned with the 
currently described mixture may be considered as a useful strategy even in a clinical 
setting.
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